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Toxins are an ancient mechanism of interaction between cohabiting organisms: basal concentrations 
serve as an informal cue, enough as a warning signal; too much and the dialog is over. As such, the 
evolutionary race to arms led to the development of a vast trove of molecular unique biochemical 
mechanisms, from small molecules to protein toxins. The study of these mechanisms is not only 
essential for the treatment of toxin-related pathologies, but also as the potential source for novel 
therapeutic drugs. 
In this thesis, a series of studies of different toxins and toxin-like proteins are compiled. To further 
understand the biological function and relevance of each toxin, their detailed study and 
characterization were pursued. Here are described the advances made using a combination of 
different complementary biophysical and structural methods, chosen in each case to specifically 
target each molecule characteristics. In the first chapter, the general biological theme of this thesis is 
introduced: toxins, particularly protein toxins, their description, and classification, as well as the role 
of structural biology in the study of proteins in general. To set the theoretical background of the 
following chapters, are also described the general principles of two of the most prominent methods 
for the study of proteins in structural biology: nuclear magnetic resonance (NMR) spectroscopy, and 
X-ray diffraction. In the second chapter, the interaction between human FKBP12 chaperone protein
and two similar bacterial small molecule toxins is detailed: rapamycin initially used as an anti-fungal
before the discovery of its potent immunosuppressive properties as a mTOR inhibitor; and
mycolactone, a bacterial toxin responsible for the disease Buruli ulcers in humans. In the third chapter,
the cell-free protein expression system is introduced as a technique best suited for the expression of
cytotoxic proteins and otherwise difficult targets, as explored further in the following chapters. In the
fourth chapter, advancements towards the structural and conformational characterization of the
membrane-inserted state of two similar pore-forming toxins are detailed: the bacterial Colicin Ia
protein; and the human Bax protein, an apoptosis effector; using X-ray crystallography, solution NMR
and solid-state NMR. Finally, in the fifth chapter, two FIC-domain bacterial toxins are investigated: the
bacterial VbhTA toxin-antitoxin protein complex, and the structural determination with its cognate
target, DNA GyraseB enzyme; and the auto-activation of the bacterial NmFIC protein; in both cases

















1. General introduction 
1.1. Toxins 
Toxins are the collective term given to a broad family of toxic molecules produced by different 
organisms, from microorganisms to animals. Their sole purpose is to directly exploit the negative 
impact on target organisms, towards maximizing the chances of survival of the producer organism. 
Thus, toxicity occurs upon direct toxin contact or absorption by the target organism. Different 
organisms produce a structural and functional diverse molecular set of toxins, with widely different 
mechanisms of action and consequently targets. Toxins exert their function through interaction with 
membranes, cell-receptors, enzymes, or other macromolecules of the target organism, which lead to 
the impairment or even disruption of its homeostasis (1, 2).  
Prokaryotic toxins are kept in an inactive state due to either the lack of a cognate target, or complex 
formation with a specific antitoxin. Hence, toxins are released either through excretion (exotoxins) or 
cell lysis (endotoxins), targeting hosts through different transport systems such as secretory systems, 
pore-formation, host-receptor binding, and other endocytic pathways (3–5). 
Eukaryotic toxins are termed venoms and exhibit two main functions: predation and defense. The 
complex chemical composition of venoms encompasses a mixture of different toxin types, often 
targeting several targets. For instance, each of the hundreds of cone snail species (genus Conus) has a 
specific venom profile, containing a mixture of up to thousands of different peptides, each targeting 
a specific target organism receptor (6, 7). 
A constant survival pressure represents the driving force for the continuous pursuit of novel toxins 
with new biochemical properties, aiming towards new targets. In fact, toxin-encoding genes are 
evolutionary hot spots within genomes, which lead to highly complex and diverse toxins (8, 9). In 
general, the increase in organism complexity from prokaryotes to eukaryotes led to the increase of 
both functional and structural complexity of toxins, from small molecules to peptides, and protein 
toxins. Moreover, below are described the known distinct toxin classes. 
1.1.1. Small molecule toxins 
Small molecule toxins are a vast family of organic molecules of low molecular mass produced by 
different organisms. Due to wild habitat and nutrient competition, bacteria, cyanobacteria, fungi, and 
other species have developed a diverse arsenal of small molecule toxins, ranging from alkaloids and 
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macrolides to polyamines, which target host protein receptors as well as enzymes with distinct 
mechanisms and pathologies (1, 3, 5, 10). As an example, the Ochratoxin, a common food contaminant 
produced by the Penicillium and Aspergillus fungi species, is a known nephrotoxic with pleiotropic 
effects in animals including humans, such as inhibition of macromolecular synthesis, increased lipid 
peroxidation and inhibition of mitochondrial respiration (11, 12). Furthermore, small molecule toxins 
are also found in the venom of several animal species (13). In chapter 3, two examples of small 
molecule toxins and their interaction with a cognate protein target are described and discussed: the 
known complex of rapamycin with the FK-506 binding protein 12 kilodalton (FKBP12), and the 
proposed complex of the exotoxin mycolactone with the FKBP12 protein. 
1.1.2. Peptide toxins 
Peptide toxins are expressed by many organisms with different activities, and are mostly categorized 
into three classes: receptor-binding peptides, as ion channels activity modulators (6, 13, 14); 
membrane destabilizing/permeating peptides (13–15); and enzyme inhibitors (16, 17). Accordingly, 
peptide toxins exhibit a variety of pathologies, though much of their properties, cellular targets, and 
functional mechanisms remain poorly understood. For instance, the cone snail produces peptides 
termed conotoxins for both defense and predation. These conotoxins are hypervariable peptides, 
known to modulate the ion channel activity of the target organism (6, 7). 
1.1.3. Protein toxins 
Protein toxins are a vast group of proteins with widely diverse targets and mechanisms of action (2). 
Toxins target the host organism essentially at three levels: extracellular space, including tissues and 
fluids; cell membrane; and intracellular space. Membrane interacting toxins can be further classified 
according to their mechanism: receptor modulators, membrane disruptors, and pore-formers. 
Extracellular toxins 
Certain toxins act on host fluids and tissues by the impairment of host defenses to further promote 
toxin and pathogen diffusion. Snake venom serine proteases are known to modulate the host 
homeostasis such as blood coagulation, blood pressure, fibrinolysis, and the complement as well as 
nervous systems in addition to prompting host tissue-digestion (18–20). 
Receptor modulator toxins 
This group of toxins binds directly to a host cell membrane cognate receptor, leading to the disruption 






Certain  toxins  disrupt  host membrane  integrity  to  facilitate  pathogen  dissemination  and  promote 
disease. As such, the first ever described toxin enzyme: Clostridium perfringens phospholipase α‐toxin, 
is  the major  pathogenic  factor  responsible  for  the  infection Clostridial myonecrosis,  known as  the 
common  gas  gangrene  (23).  The  phospholipase  cleaves  phospholipids  into  smaller  secondary 
messengers to disrupt the host’s signaling, promoting further infection (24). 
Pore‐forming toxins 
Pore‐forming  protein  toxins  (PFTs)  are  one  of  Nature’s  most  common  and  effective  biochemical 
weapons.  These  toxins  are  found  in  a  wide  range  of  organisms,  particularly  bacteria,  yet  share 
remarkable domain organization, structure, and function (25, 26). PFTs are classified according to the 



































organism. Due to the complexity of cell-machinery, toxins have evolved to exploit most of the cell 
macromolecular infrastructures, often in a pleiotropic fashion. For instance, the E. coli secreted 
protein G (EspG), from enterohaemorrhagic E. coli, is implicated in tight junction disruption (37, 41). 
In the host-cell, EspG binds non-covalently to the host guanosine triphosphate (GTP) hydrolases 
(GTPases) of the ADP-ribosylation factor (ARF) family, locking them in the active ARF-GTP complex 
state, which in turn inhibits endogenous-ligand binding, effectively blocking Golgi traffic (42).  
Enzyme-catalyzed PTM is a common mechanism to alter protein function through covalent 
attachment or removal of functional groups, such as AMPylation: the catalytic addition of an 
adenosine monophosphate (AMP) group. The filamentation induced by cyclic AMP (FIC) protein 
family, targets proteins for PTM altering their endogenous function, usually through AMPylation. This 
family is found in most organisms (38), whereas in bacteria these are present as toxin-antitoxin (TA) 
complexes, which use different modification mechanisms to modulate host physiology. Interestingly, 
FIC proteins are also present in eukaryotic organisms. The human Huntingtin yeast-interaction protein 
E (HypE) protein acts as an on-off switch through AMPylation of the Binding immunoglobulin protein 
(BiP), a major chaperone in the unfolded protein response residing in the endoplasmatic reticulum 
(ER) (122). 
In chapter 5, the structural and functional characterization of two bacterial intracellular PTM toxins is 
described: the Neisseria meningitidis FIC (NmFIC); and the Bartonella schoenbuchensis octopine Ti 
plasmid virulence B homologous T and A complex (VbhT/A), in complex with its cognate target, the 
Escherichia coli DNA topoisomerase IIa Gyrase B (Gyr B). 
1.1.4. Toxins as drug development leads 
The unique properties of toxins such as: receptor targeting and cell type specificity (43), the capacity 
to evade the innate immune system, cell proteases and degradation systems (15, 44), as well as their 
distinctive catalytic mechanisms, make them an ideal lead for drug development and drug delivery 
(45–49). In fact, many toxins were discovered through drug lead screening programs (50). Scientific 
research and pharmaceutical industry have in the past explored toxins mostly as antibiotics, with very 
successful results, although its excessive and often neglectful use has led to the rise of multiresistant 
pathogens (51). Several potential therapeutic toxins have been described in the past (52); in fact, 
numerous toxin-based pharmaceuticals are currently in clinical trial, and some approved products 
made it to market launches (53, 54). Likewise, the pertussis toxin produced by B. pertussis, responsible 
for whooping cough, is in clinical research for its therapeutic role in a number of common diseases, 
such as hypertension (55), autoimmune diseases (56), and human immunodeficiency virus replication 
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(57). Effective research towards the better understanding of the structure and action mechanisms of 
toxins provides the basis for new therapies towards pathogenicity and venom antitoxins. Additionally, 
and more impactful, the extremely ingenious chemical space exploration of toxin molecules, paves 
the way for the development of new strategies based on toxin derivatives, towards novel therapies 
for human pathologies. 
1.2. Structural Biology for protein structure and conformation characterization 
With the advent of high-throughput genome sequencing and the completion of the Human Genome 
Project (58), as well as other genomes, the available amount of protein sequence data has grown 
exponentially. Nevertheless, the knowledge of protein sequence is not sufficient for the 
determination of protein folding and function, representing only the first step towards this goal. The 
understanding of proteome function requires extensive knowledge on both each protein’s interacting-
network, as well as their respective chemical environment; moreover, these fundamental 
characteristics depend on each distinct protein structure. Each protein’s exposed surface properties, 
such as charge, as well as hydrophobicity, minutely detail these interactions and its extent. Besides, 
protein flexibility and conformational changes further modulate the functional properties of proteins. 
Structural biology aims to determine and subsequently understand protein structures as well as 
dynamics at atomic resolution. Further, this knowledge is not limited to understand the functional 
principles of each organism, but as well to improve the current state of drug research. As a 
consequence, structural knowledge permits the use of rational design for the improvement of current 
drugs, as well as the identification of new drug leads for the research and subsequent development 
of novel drugs and therapies with improved efficacy (59). 
Currently, the three foremost techniques for structure determination at atomic or near-atomic 
resolution in biology are X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and 
cryo-electron microscopy. These research techniques vary significantly in their approach to structure 
determination. Each technique different advantages and disadvantages can be used to complement 
each other. 
X-ray crystallography uses X-ray diffraction patterns to obtain static structures of molecules of 
interest. It depends on the obtainment of well-ordered macroscopic diffracting crystals for each 
molecule, which typically requires serialization testing of crystallization conditions. X-ray 
crystallography can determine complex high-resolution structures ranging from small molecules to 
molecules as large as the prokaryotic and eukaryotic ribosomes (60, 61), but it proves ineffectual for 
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dynamic and disordered systems, as it requires periodicity. The recent advent of X-ray free-electron 
laser sources and serial femtosecond crystallography have been shown to overcome some of the 
obstacles of X-ray crystallography, such as crystal size and radiation damage, while concurrently 
possibly introducing time-resolved information (62–65). 
Cryo-electron microscopy (cryo-EM) probes molecules of interest through exposure of frozen sample 
grids to an electron beam at cryogenic temperatures. It requires minimal sample amounts while 
allowing the study of proteins with different conformations and long flexible loops. Structure 
determination relies on computer selection and averaging of thousands of particles, leading to a slow 
throughput. Since the determination of the first near-atomic resolution structures (66), cryo-EM 
structure determination has mostly relied on large and relatively stable complexes, such as ribosomes. 
Due to recent developments such as improved detector hardware, and beam-induced motion 
correction, cryo-EM is evolving at a rapid pace, currently on the verge of reaching atomic resolution 
(67, 68). As a consequence, the previous macromolecule experimental lower size limit of 300 kDa is 
closer to the theoretical size limit of 38 kDa (69), as the recently published structure of the cancer 
target isocitrate dehydrogenase with a size of 93 kDa at 3.8 Å resolution shows (70). 
Solution NMR spectroscopy allows the structure determination of macromolecules at atomic 
resolution and is ideally suited to dynamical characterization such as ligand binding, conformational 
changes, and macromolecular dynamics. A significant drawback of biomolecular NMR is its size 
limitation, as the slower molecular tumbling and shorter signal relaxation times of larger molecules 
lead to peak broadening and loss of sensitivity. Besides, the increased number of nuclei complicates 
the spectra and subsequent spectral analysis. In the last few decades, several advances in NMR 
hardware and methodology such as: increased magnetic fields and improved electronics, water 
handling, perdeuteration, transverse relaxation optimized spectroscopy (TROSY) based experiments, 
heteronuclear isotopic labeling and multidimensional experiments (71–74), have increased the 
current size limit for de novo structure determination to about 70 kDa. Furthermore, sophisticated 
labeling schemes such as methyl group labeling increased the overall limits of molecule size which can 
be quantitatively and qualitatively studied by NMR spectroscopy to 1 MDa (75, 76). 
Magic-angle spinning (MAS) solid-state NMR spectroscopy allows the study of macromolecules in the 
solid-state, where molecules typically lack motion and spin anisotropic interactions lead to peak 
broadening. This can be overcome by both fast sample spinning (77), as well as specific radiofrequency 
(rf) pulses that attenuate undesired couplings, enabling identical approaches used in solution-state. 
Theoretically, molecular size is not a limitation for solid-state NMR (78). This allows both the structural 
and dynamical characterization of huge macromolecule assemblies such as fibrils, an ideal application 
		12	
for solid-state NMR. Currently, solid-state NMR spectroscopy applications are limited due to sample 
preparation, though advancements such as faster rotor spinning which allow proton detection, are 
advancing at a fast pace (79–82). 
The different advantages and drawbacks of the previously discussed techniques have led to the 
procurement of integrated structural approaches. The NMR spectroscopy overall size limitation can 
be overcome with solid-state NMR, cryo-EM and X-ray-derived structures. The dynamic rich 
information and atomic resolution of NMR solved structures of individual monomers can be 
complemented with the higher-sized complex structures achievable with both techniques. For 
instance, the recent structure and assembly determination of the apoptosis-associated speck-like 
protein containing a CARD (ASC)-filament, was solved with an iterative algorithm using an ensemble 
of cryo-EM, solution, and solid-state NMR data in an integrated fashion (83). 
1.2.1. NMR spectroscopy principles 
NMR uses the spin angular momentum and magnetic moment of nuclei to study its local chemical 
environment. A non-zero nuclear spin (S) is associated with a magnetic moment (μ) via the relation 
μ = γ . S 
where γ is the nuclear gyromagnetic ratio (84–86). In the absence of an external magnetic field, the 
nuclei are oriented randomly. Under an external magnetic field (B0) the bulk magnetization precesses 
around the magnetic field (Figure 1-3) with a frequency 
ω0 = γ . B0 
known as the Larmor frequency (84, 87). 
	
Figure 1-3 – Spin precession. On the left is depicted the spin precession under an external field B0. On the right 
is shown the z-axis projection of the magnetic moment, the bulk magnetization. 
Since γ is nucleus-type specific, each nucleus has a specific Larmor frequency. The Larmor frequency 
is independent of the angle between the magnetic field and the magnetic moment direction. A 
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specific  chemical  environment  within  the  bulk  magnetization  slightly  changes  its  precessing 
















transformation yields a frequency vs. intensity 1D plot as exemplified in Figure 1-5 (102). Also, to 



























Figure 1-5 – A periodic function f (black), is composed of individual sinusoidal components (blue, green and 
red) with different amplitudes (A, B, C) and frequencies (a,b,c). A Fourier transform deconvolutes the time-
domain signal sum, such as an FID, into the frequency domain, the specific frequencies of each sinusoid that 
constitute it. 
2D NMR 
Signal overlap due to the high number of homonuclear spins present in macromolecules results in 
complicated, frequency-overcrowded spectra. Therefore, the complex analysis of 1D spectra led to 
the extension of NMR experiments from one to two dimensions (103). In two-dimensional NMR the 
signal is recorded as a function of two time variables, t1 and t2, where the evolution time t1 is stepwise 
increased, and for each different t1 an FID is recorded. As a result, two Fourier transformations take 
place one as a function of t1 and the second as a function of t2, yielding a spectrum function of two 
frequency variables F1 and F2 as depicted in Figure 1-6 (104). 
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  Figure 1‐6 – 2D‐NMR spectrum following the second Fourier transform. In A is shown a 2D‐ homonuclear type 
spectrum,  where  F1  and  F2  frequencies  correspond  to  the  same  type  of  nucleus.  In  B  is  shown  a  2D‐ 
heteronuclear type spectrum, where F1 and F2 correspond to the frequencies of distinct nuclei types.  
The  introduction  of  a  second  dimension  allows  to  better  resolve  overlapping  signals  in  1D NMR‐
spectra, it also helps obtain new chemical shift information. Correlation experiments can differ on the 
type  of  magnetization  transfer.  Homonuclear  correlation  spectroscopy,  such  as  correlation 
spectroscopy  (COSY)  and  total  correlation  spectroscopy  (TOCSY)  identify  same  isotope  correlated 
spins, e.g., the HN‐Hα pair (105, 106).  In two‐dimensional homonuclear correlation spectra, both F1 
and F2  frequencies  result  from the same  isotope usually  1H. Diagonal peaks correspond  to  the 1D 
isotope  spectrum;  off‐diagonal  peaks  have  different  frequencies  in  each  axis  and  correspond  to 
coupled  resonances  (Figure  1‐6‐A).  In  a  TOCSY  experiment,  between  the  evolution  period  and 
acquisition, a composite spin‐lock pulse is introduced during the mixing time (Figure 1‐7). Spin‐locking 
achieves  an  isotropic  mixing  of  protons,  resulting  in  coherence  transfer  between  coupled  spins 








the  F1  dimension  the  ‐NH  1H  (108).  The  2D  plot  shows  resonance  peaks  for  each  –NH  and  its 
distinctness is often termed as the protein’s fingerprint spectra. Peak chemical shift dispersion is a 






and  through‐space  [1H,1H]–NOESY  (104,  112)  spectra.  Spectral  analysis  for  larger  molecules  is 
complicated due  to peak  crowding.  To  solve  this, multi‐dimensional NMR experiments, which  can 
correlate three types of nuclei, 1H, 15N, and 13C have been developed. As depicted in Figure 1‐8, the 
spread  of  resonances  through  a  new  dimension  effectively  reduces  overlap,  allowing  sequential 
assignment and extraction of additional chemical shift information from these nuclei. In protein NMR, 
these  are  used  for  the  specific  backbone  and  side‐chain  resonance  assignment  (113).  Moreover, 








After complete assignment, backbone and side-chain chemical shift data can be used to determine 
protein secondary structure (114, 115). From scalar coupling data, protein dihedral angles can be 
derived (116). Other phenomena such as the NOE, and residual dipolar couplings can be used as 
conformational restraints for structural characterization; and relaxation data can be used to derive 
protein dynamics information (109, 117, 118). Finally, in the last step towards structure 
determination, an ensemble of structures is calculated and refined in agreement with the restraint 
data, which leads to the characterization of the structure and conformation of a specific 
macromolecule or complex of macromolecules. 
1.2.2. X-ray crystallography principles 
Structural X-ray crystallography uses X-ray scattering to study molecules of interest. Contrary to visible 
light (λ=400–700 nm), X-ray radiation (λ≈1 Å) is able to diffract with the electron cloud of molecules. 
Macroscopic crystals are composed of highly similar structural motifs that form each unit cell, 
repeated periodically throughout the whole crystal. As each molecule diffracts X-rays identically, a 
massive enhancement of identical constructive scattering events produces a measurable diffraction 
pattern. From it, it is possible to obtain an image of the electron clouds that surround the molecules 
in the crystal, and consequently a model of the molecule’s structure (119). 
Protein crystallization 
The study of protein structure using X-rays requires high-quality protein crystals. Proteins crystals are 
grown through slow, controlled precipitation from aqueous solution under conditions that do not 
denature the protein, while increasing the protein and precipitant concentrations through 
evaporation, commonly by vapor diffusion. Under certain conditions, molecules solidify to form a 
crystal, with individual proteins adopting one or a few identical orientations resulting in a three-
dimensional molecule matrix-bound through non-covalent interactions, hydrogen bonds and salt-
bridges (120-121). 
After protein purification, crystallization serial trials are set up with common crystallization buffers in 
search for crystal formation. After a successful condition is found, this is then finely optimized for 
crystal quality and size, suitable for diffraction measurement. Seeding with crushed pre-formed 
crystals can also be attempted for further optimization. As proteins often interact with partners or 
ligands, in order to understand these interactions and their effect on structure, proteins can be co-
crystallized with its partner, or even soaked in the crystalline form with it, if small enough to diffuse 






symmetry  operations  is  termed  the  asymmetric  unit,  shown  in  Figure  1‐9;  and  the  symmetry 




molecule’s atom, with one of  the vertices as  its origin  (x,y,z=[0,0,0])  (Figure 1‐9).   Each unit  cell  is 
composed by an infinite number of atom planes, which diffract an incoming X‐ray at a particular angle 




From each reflection both the position, which correlates with the diffraction angle and the intensity 
of the diffracted spots can be measured. The distances between reflection spots outline the reciprocal 
lattice, which inversely correlates with the crystal (real) lattice. In reciprocal space, each reflection 
defined by a set of coordinates (h,k,l), correspond to a family of diffracting atom planes in real space. 
Counting from the center of reflections h,k,l=[0,0,0], an integer coordinate is given to each reflection 
during indexing. Moreover, the intensity of each reflection relates to the positions of electrons in real 
space (122). 
As a crystal is a three-dimensional lattice, its rotation (from the X-ray beam) exposes a different 
section of atom planes capable of diffraction and therefore a different diffraction pattern. Therefore, 
through crystal rotation, it is possible to obtain the full three-dimensional diffraction pattern that 
describes the three-dimensional unit cell. In other words, the crystal structure is encoded in the 
diffracted X-rays, the shape and symmetry of the unit cell define the directions of the diffracted 
beams, and the locations of all atoms in the unit cell define their intensities. 
From diffraction to structure 
Each diffracted X-ray that produces a reflection is the sum of the contributions of all scatterers in the 
unit cell, described as a Fourier sum, the structure factor equation Fhkl (122). Each scattered X-ray 
wave is characterized by an amplitude, frequency, and phase, however, unlike the amplitude and 
frequency, it is not possible to infer the hitting wave’s phase from its diffraction pattern reflection. 
In order to characterize the electron distribution in the asymmetric unit of the unit cell, it is necessary 
to obtain the phases, in what is known as the phase problem. Different methods exist to solve this, 
being the most popular heavy metal insertion, molecular replacement, in the case where a 
homologous structure is known and increasingly anomalous diffraction (123). 
After solving the phase problem, through the Fourier transform of the structure factors sum, it is 
possible to obtain an initial approximate electron-density distribution. The known residue sequence 
enables model building in a chemical and conformational appropriate state that fits the electron 
density map. This can be improved in an iterative fashion between model building and refinement 












are described.  In  the  fourth  chapter,  two examples of pore‐forming  toxins  are described,  and  the 
advances towards their membrane‐inserted characterization, using solution NMR spectroscopy, solid‐
state NMR spectroscopy, and X‐ray crystallography are described. Finally,  in  the  fifth chapter,  two 





1.  J. J. P. Genevieve S. Bondy, James J. Pestka, Immunomodulation By fungal toxins. J. Toxicol. 
Environ. Heal. Part B. 3, 109–143 (2000). 
2.  D. Ladant, J. E. Alouf, M. R. Popoff, The comprehensive sourcebook of bacterial protein toxins 
(Elsevier, ed. 3, 2006). 
3.  M. M. Lubran, Bacterial toxins. Ann. Clin. Lab. Sci. 18, 58–71 (1988). 
4.  T.-T. Tseng, B. M. Tyler, J. C. Setubal, Protein secretion systems in bacterial-host associations, 
and their description in the Gene Ontology. BMC Microbiol. 9, S2 (2009). 
5.  K. Sandvig, M. L. Torgersen, N. Engedal, T. Skotland, T. G. Iversen, Protein toxins from plants 
and bacteria: Probes for intracellular transport and tools in medicine. FEBS Lett. 584, 2626–
2634 (2010). 
6.  W. R. Gray, B. M. Olivera, L. J. Cruz, Peptide toxins from venomous conus snails. Annu. Rev. 
Biochem. 57, 665–700 (1988). 
7.  H. Terlau, Conus Venoms: A rich source of novel ion channel-targeted peptides. Physiol. Rev. 
84, 41–68 (2004). 
8.  K. Nakashima et al., Accelerated evolution in the protein-coding regions is universal in 
crotalinae snake venom gland phospholipase A2 isozyme genes. Proc. Natl. Acad. Sci. U. S. A. 
92, 5605–5609 (1995). 
9.  L. H. Liow, L. Van Valen, N. C. Stenseth, Red Queen: From populations to taxa and communities. 
Trends Ecol. Evol. 26, 349–358 (2011). 
10.  H. M. Liyanage, D. N. M. Arachchi, T. Abeysekara, L. Guneratne, Toxicology of freshwater 
cyanobacteria. J. Environ. Sci. Heal. Part C. 501, 137–168 (2016). 
11.  J. L. Richard, G. A. Bray, D. H. Ryan, Mycotoxins as immunomodulators in animal systems. 
Mycotoxins, Cancer, Heal., 197–220 (1991). 
12.  T. Kuiper-Goodman, P. M. Scott, Risk assessment of the mycotoxin ochratoxin A. Biomed. 
Environ. Sci. 2, 179–248 (1989). 
13.  G. Corzo, P. Escoubas, Pharmacologically active spider peptide toxins. Cell. Mol. Life Sci. 60, 
2409–2426 (2003). 
14.  T. Honma, K. Shiomi, Peptide toxins in sea anemones: Structural and functional aspects. Mar. 
Biotechnol. 8, 1–10 (2006). 
15.  D. J. Craik, Plant cyclotides: Circular, knotted peptide toxins. Toxicon. 39, 1809–1813 (2001). 
16.  S. H. Chiou et al., Inhibition of protein kinase C by snake venom toxins: comparison of enzyme 
inhibition, lethality and hemolysis among different cardiotoxin isoforms. Biochem. Mol. Biol. 
Int. 35, 1103–1112 (1995). 
17.  R. . Dawson, The toxicology of microcystins. Toxicon. 36, 953–962 (1998). 
18.  T. Matsui, Y. Fujimura, K. Titani, Snake venom proteases affecting hemostasis and thrombosis. 
Biochim. Biophys. Acta 1477, 146–156 (2000). 
19.  R. M. Kini, Serine proteases affecting blood coagulation and fibrinolysis from snake venoms. 
Pathophysiol. Haemost. Thromb. 34, 200–204 (2005). 
20.  T. Morita, Structures and functions of snake venom CLPs (C-type lectin-like proteins) with 
anticoagulant-, procoagulant-, and platelet-modulating activities. Toxicon. 45, 1099–1114 
(2005). 
21.  A. V. Osipov et al., Naturally occurring disulfide-bound dimers of three-fingered toxins: A 
paradigm for biological activity diversification. J. Biol. Chem. 283, 14571–14580 (2008). 
22.  O. H. Del Brutto, V. J. Del Brutto, Neurological complications of venomous snake bites: A 
review. Acta Neurol. Scand. 125, 363–372 (2012). 
23.  M. G. Macfarlane, B. C. J. G. Knight, The biochemistry of bacterial toxins. Biochem. J. 42, 590–
595 (1948). 
24.  J. Sakurai, M. Nagahama, M. Oda, Clostridium perfringens α-toxin: Characterization and mode 
of action. J. Biochem. 136, 569–574 (2004). 
		22	
25.  M. W. Parker, S. C. Feil, Pore-forming protein toxins: From structure to function. Prog. Biophys. 
Mol. Biol. 88, 91–142 (2005). 
26.  G. Anderluh, J. H. Lakey, Disparate proteins use similar architectures to damage membranes. 
Trends Biochem. Sci. 33, 482–490 (2008). 
27.  J. Rossjohn, S. C. Feil, W. J. McKinstry, R. K. Tweten, M. W. Parker, Structure of a cholesterol-
binding, thiol-activated cytolysin and a model of its membrane form. Cell. 89, 685–692 (1997). 
28.  M. Fivaz, L. Abrami, Y. Tsitrin, F. G. van der Goot, Aerolysin from Aeromonas hydrophila and 
related toxins. Curr. Top. Microbiol. Immunol. 257, 35–52 (2001). 
29.  R. K. Tweten, M. W. Parker, A. E. Johnson, The cholesterol-dependent cytolysins. Curr. Top. 
Microbiol. Immunol. 257, 15–33 (2001). 
30.  P. Boonserm, P. Davis, D. J. Ellar, J. Li, Crystal structure of the mosquito-larvicidal toxin Cry4Ba 
and its biological implications. J. Mol. Biol. 348, 363–382 (2005). 
31.  N. Galitsky et al., Structure of the insecticidal bacterial δ-endotoxin Cry3Bb1 of Bacillus 
thuringiensis. Acta Crystallogr. Sect. D Biol. Crystallogr. 57, 1101–1109 (2001). 
32.  C. E. . E. D. Bell, Crystal structure of nucleotide-free diphtheria toxin. Biochemistry. 36, 481–
488 (1997). 
33.  K. J. Oh et al., Organization of diphtheria toxin T domain in bilayers: A site-directed spin labeling 
study. Science 273, 810–812 (1996). 
34.  M. E. Pipkin, J. Lieberman, Delivering the kiss of death: progress on understanding how perforin 
works. Curr. Opin. Immunol. 19, 301–308 (2007). 
35.  P. E. Czabotar, G. Lessene, A. Strasser, J. M. Adams, Control of apoptosis by the BCL-2 protein 
family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49–63 (2014). 
36.  D. Butzke, A. Luch, High-molecular weight protein toxins of marine invertebrates and their 
elaborate modes of action. Molecular, Clinical and Environmental Toxicology 100, 213–232 
(2010). 
37.  K. Aktories, Bacterial protein toxins that modify host regulatory GTPases. Nat. Rev. Microbiol. 
9, 487–498 (2011). 
38.  A. Harms, F. V. Stanger, C. Dehio, Biological diversity and molecular plasticity of FIC domain 
proteins, Annu Rev Microbiol. 70, 341–360 (2016). 
39.  C. E. Bell, D. Eisenberg, Crystal structure of diphtheria toxin bound to nicotinamide adenine 
dinucleotide. Biochemistry. 35, 1137–1149 (1996). 
40.  K. J. F. Satchell, Actin Crosslinking Toxins of Gram-Negative Bacteria. Toxins. 1, 123–133 (2009). 
41.  J. A. Guttman, B. B. Finlay, Tight junctions as targets of infectious agents. Biochim. Biophys. 
Acta. 1788, 832–841 (2009). 
42.  A. S. Selyunin et al., The assembly of a GTPase-kinase signalling complex by a bacterial catalytic 
scaffold. Nature. 469, 107–111 (2011). 
43.  K. Strebhardt, A. Ullrich, Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. 
Cancer. 8, 473–480 (2008). 
44.  B. G. Fry et al., The toxicogenomic multiverse: convergent recruitment of proteins into animal 
venoms. Annu. Rev. Genomics Hum. G. 10, 483–511 (2009). 
45.  P. Escoubas, F. Bosmans, Spider peptide toxins as leads for drug development. Expert Opin. 
Drug Discov. 2, 823–835 (2007). 
46.  Y. N. Utkin, Animal venom studies: Current benefits and future developments. World J. Biol. 
Chem. 6, 28–33 (2015). 
47.  J. Chaisakul, W. C. Hodgson, S. Kuruppu, N. Prasongsook, Effects of animal venoms and toxins 
on hallmarks of cancer. J Cancer. 7, 1571–1578 (2016). 
48.  L. González-Mariscal et al., Strategies that target tight junctions for enhanced drug delivery. 
Curr. Pharm. Des. 22, 1–1 (2016). 
49.  R. Mir, S. Karim, M. Kamal, C. Wilson, Z. Mirza, Conotoxins: Structure, therapeutic potential 
and pharmacological applications. Curr. Pharm. Des. 22, 582–589 (2016). 
50.  W. Bergmann, R. J. Feeney, Contributions to the study of marine products. XXXII. The 
		 23	
nucleosides of sponges. J. Org. Chem. 16, 981–987 (1951). 
51.  D. M. Cornforth, K. R. Foster, Antibiotics and the art of bacterial war. Proc. Natl. Acad. Sci. 112, 
10827–10828 (2015). 
52.  A. Pickett, K. Perrow, Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins. 
1, 63–81 (2011). 
53.  S. Potala, S. K. Sahoo, R. S. Verma, Targeted therapy of cancer using diphtheria toxin-derived 
immunotoxins. Drug Discov. Today. 13, 807–815 (2008). 
54.  Z. Takacs, N. York, Animal venoms in medicine. Encycl. Toxicol. 1, 252–259 (2014). 
55.  C. Kost, W. A. Herzer, P. J. Li, E. K. Jackson, Pertussis toxin-sensitive G-proteins and regulation 
of blood pressure in the spontaneously hypertensive rat. Clin. Exp. Pharmacol. Physiol. 26, 449–
455 (1999). 
56.  Z. Tang et al., Pertussis toxin attenuates experimental autoimmune encephalomyelitis by 
upregulating neuronal vascular endothelial growth factor. Neuroreport. 24, 469–475 (2013). 
57.  C. Rizzi et al., Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine 
expression in chronically infected U1 cells via inhibition of activator protein 1. J Immunol. 176, 
999–1006 (2006). 
58.  I. Human Genome Sequencing Consortium, Finishing the euchromatic sequence of the human 
genome. Nature. 431, 931–945 (2004). 
59.  A. C. Anderson, The process of structure-sased drug design. Chem. Biol. 10, 787–797 (2003). 
60.  A. Korostelev, S. Trakhanov, M. Laurberg, H. F. Noller, Crystal structure of a 70S ribosome-tRNA 
complex reveals functional interactions and rearrangements. Cell. 126, 1065–1077 (2006). 
61.  A. Ben-Shem et al., The structure of the eukaryotic ribosome at 3.0 A resolution. Science. 334, 
1524–1529 (2011). 
62.  R. Neutze, J. Hajdu, Femtosecond time resolution in X-ray diffraction experiments. Proc. Natl. 
Acad. Sci. 94, 5651–5655 (1997). 
63.  E. E. Lattman, Molecular structures from femtosecond X-ray pulses. Proc. Natl. Acad. Sci. 98, 
6535–6536 (2001). 
64.  H. N. Chapman et al., Femtosecond diffractive imaging with a soft-X-ray free-electron laser. 
Nat. Phys. 2, 839–843 (2006). 
65.  H. N. Chapman et al., Femtosecond X-ray protein nanocrystallography. Nature. 470, 73–77 
(2011). 
66.  R. Henderson et al., Model for the structure of bacteriorhodopsin based on high-resolution 
electron cryo-microscopy. J. Mol. Biol. 213, 899–929 (1990). 
67.  A.-C. Milazzo et al., Initial evaluation of a direct detection device detector for single particle 
cryo-electron microscopy. J. Struct. Biol. 176, 404–408 (2011). 
68.  X. Li et al., Electron counting and beam-induced motion correction enable near-atomic-
resolution single-particle cryo-EM. Nat. Methods. 10, 584–590 (2013). 
69.  R. Henderson, The potential and limitations of neutrons, electrons and X-rays for atomic 
resolution microscopy of unstained biological molecules. Q. Rev. Biophys. 28, 171–193 (2009). 
70.  A. Merk et al., Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery. Cell (2016). 
71.  M. Salzmann, K. Pervushin, G. Wider, H. Senn, K. Wüthrich, TROSY in triple-resonance 
experiments: New perspectives for sequential NMR assignment of large proteins. Proc. Natl. 
Acad. Sci. 95, 13585–13590 (1998). 
72.  S. Hiller, G. Wider, T. Etezady-Esfarjani, R. Horst, K. Wüthrich, Managing the solvent water 
polarization to obtain improved NMR spectra of large molecular structures. J. Biomol. NMR. 
32, 61–70 (2005). 
73.  S. W. Fesik, E. R. P. Zuiderweg, Heteronuclear three-dimensional NMR spectroscopy of 
isotopically labelled biological macromolecules. Q. Rev. Biophys. 23, 97–131 (1990). 
74.  D. M. LeMaster, F. M. Richards, NMR sequential assignment of Escherichia coli thioredoxin 
utilizing random fractional deuteriation. Biochemistry. 27, 142–150 (1988). 
75.  J. Fiaux, E. B. Bertelsen, A. L. Horwich, K. Wüthrich, NMR analysis of a 900K GroEL GroES 
		24	
complex. Nature. 418, 207–211 (2002). 
76.  R. Sprangers, L. E. Kay, Quantitative dynamics and binding studies of the 20S proteasome by 
NMR. Nature. 445, 618–622 (2007). 
77.  E. R. Andrew, A. Bradbury, R. G. Eades, Nuclear magnetic resonance spectra from a crystal 
rotated at high speed. Nature. 182, 1659–1659 (1958). 
78.  Vaughan; W. Robert, R. W. Vaughan, R. W. Vaughan, High-resolution, solid state NMR. Annu. 
Rev. Phys. Chem. 29, 397–419 (1978). 
79.  M. J. Knight et al., Fast resonance assignment and fold determination of human superoxide 
dismutase by high-resolution proton-detected solid-state MAS NMR spectroscopy. Angew. 
Chemie Int. Ed. 50, 11697–11701 (2011). 
80.  D. H. Zhou et al., Solid-state NMR analysis of membrane proteins and protein aggregates by 
proton detected spectroscopy. J. Biomol. NMR. 54, 291–305 (2012). 
81.  R. Zhang, K. H. Mroue, A. Ramamoorthy, Proton chemical shift tensors determined by 3D 
ultrafast MAS double-quantum NMR spectroscopy. J. Chem. Phys. 143, 1442011–1442016 
(2015). 
82.  E. Barbet-Massin et al., Rapid proton-detected NMR assignment for proteins with fast magic 
angle spinning. J. Am. Chem. Soc. 136, 12489–12497 (2014). 
83.  L. Sborgi et al., Structure and assembly of the mouse ASC inflammasome by combined NMR 
spectroscopy and cryo-electron microscopy. Proc. Natl. Acad. Sci. 112, 13237–13242 (2015). 
84.  J. Larmor, LXIII. On the theory of the magnetic influence on spectra; and on the radiation from 
moving ions. Philos. Mag. Ser. 5. 44, 503–512 (1897). 
85.  W. Pauli, Zur Frage der theoretischen Deutung der Satelliten einiger Spektrallinien und ihrer 
Beeinflussung durch magnetische Felder. Naturwissenschaften. 12, 741–743 (1924). 
86.  P. A. M. Dirac, The Principles of Quantum Mechanics (Oxford University Press, 1930). 
87.  J. Larmor, Aether and Matter (Cambridge University Press, 1900). 
88.  P. Zeeman, VII. Doublets and triplets in the spectrum produced by external magnetic forces. 
Philos. Mag. Ser. 5. 44, 55–60 (1897). 
89.  C. P. Slichter, Principles of Magnetic Resonance (Springer Berlin Heidelberg, ed. 2, 1978), vol. 1 
of Springer Series in Solid-State Sciences. 
90.  W. G. Proctor, F. C. Yu, The dependence of a nuclear magnetic resonance frequency upon 
chemical compound. Phys. Rev. 77, 717–717 (1950). 
91.  N. F. Ramsey, Magnetic shielding of nuclei in molecules. Phys. Rev. 78, 699–703 (1950). 
92.  G. Lindström, An experimental investigation of the nuclear magnetic moments of D2 and H1. 
Physica. 17, 412–419 (1951). 
93.  H. S. Gutowsky, D. W. McCall, C. P. Slichter, Coupling among nuclear magnetic dipoles in 
molecules. Phys. Rev. 84, 589–590 (1951). 
94.  E. L. Hahn, D. E. Maxwell, Chemical shift and field independent frequency modulation of the 
spin echo envelope. Phys. Rev. 84, 1246–1247 (1951). 
95.  N. F. Ramsey, E. M. Purcell, Interactions between nuclear spins in molecules. Phys. Rev. 85, 
143–144 (1952). 
96.  G. E. Pake, Nuclear resonance absorption in hydrated crystals: fine structure of the proton line. 
J. Chem. Phys. 16, 327–336 (1948). 
97.  H. S. Gutowsky, G. B. Kistiakowsky, G. E. Pake, E. M. Purcell, Structural investigations by means 
of nuclear magnetism. I. Rigid Crystal Lattices. J. Chem. Phys. 17, 972–981 (1949). 
98.  E. M. Purcell, H. C. Torrey, R. V. Pound, Resonance absorption by nuclear magnetic moments 
in a solid. Phys. Rev. 69, 37–38 (1946). 
99.  J. H. Van Vleck, The dipolar broadening of magnetic resonance lines in crystals. Phys. Rev. 74, 
1168–1183 (1948). 
100.  F. Bloch, Nuclear induction. Phys. Rev. 70, 460–474 (1946). 
101.  E. L. Hahn, Nuclear induction due to free larmor precession. Phys. Rev. 77, 297–298 (1950). 
102.  R. R. Ernst, Application of fourier transform spectroscopy to magnetic resonance. Rev. Sci. 
		 25	
Instrum. 37, 93–102 (1966). 
103.  R. R. Ernst, G. Bodenhausen, A. Wokaun, Principles of nuclear magnetic resonance in one and 
two dimensions (Clarendon Press, 1988). 
104.  J. Jeener, B. H. Meier, P. Bachmann, R. R. Ernst, Investigation of exchange processes by two-
dimensional NMR spectroscopy. J. Chem. Phys. 71, 4546–4553 (1979). 
105.  W. P. Aue, E. Bartholdi, R. R. Ernst, Two-dimensional spectroscopy. Application to nuclear 
magnetic resonance. J. Chem. Phys. 64, 2229–2246 (1976). 
106.  A. Bax, D. G. Davis, MLEV-17-based two-dimensional homonuclear magnetization transfer 
spectroscopy. J. Magn. Reson. 65, 355–360 (1985). 
107.  R. H. Griffey, A. G. Redfield, Proton-detected heteronuclear edited and correlated nuclear 
magnetic resonance and nuclear Overhauser effect in solution. Q. Rev. Biophys. 19, 51–82 
(1987). 
108.  G. Bodenhausen, D. J. Ruben, Natural abundance nitrogen-15 NMR by enhanced heteronuclear 
spectroscopy. Chem. Phys. Lett. 69, 185–189 (1980). 
109.  K. Wüthrich, NMR of Proteins and Nucleic Acids (Wiley-Interscience, ed. 1, 1987). 
110.  W. P. Aue, Two-dimensional spectroscopy. Application to nuclear magnetic resonance. J. 
Chem. Phys. 64, 2229–2246 (1976). 
111.  L. Braunschweiler, R. . Ernst, Coherence transfer by isotropic mixing: Application to proton 
correlation spectroscopy. J. Magn. Reson. 53, 521–528 (1983). 
112.  A. Kumar, R. R. Ernst, K. Wüthrich, A two-dimensional nuclear Overhauser enhancement (2D 
NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in 
biological macromolecules. Biochem. Biophys. Res. Commun. 95, 1–6 (1980). 
113.  J. Cavanagh, W. J. Fairbrother, A. G. Palmer, M. Rance, N. J. Skelton, in Protein NMR 
Spectroscopy (Elsevier, ed. 2, 2007). 
114.  D. S. Wishart, B. D. Sykes, F. M. Richards, The chemical shift index: a fast and simple method 
for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry. 
31, 1647–1651 (1992). 
115.  D. Wishart, B. Sykes, The 13C Chemical-Shift Index: A simple method for the identification of 
protein secondary structure using 13C chemical-shift data. J. Biomol. NMR. 4 (1994). 
116.  J. C. Hoch, C. M. Dobson, M. Karplus, Vicinal coupling constants and protein dynamics. 
Biochemistry. 24, 3831–3841 (1985). 
117.  N. Tjandra, Direct measurement of distances and angles in biomolecules by NMR in a dilute 
liquid crystalline medium. Science. 278, 1111–1114 (1997). 
118.  J. R. Tolman, J. M. Flanagan, M. A. Kennedy, J. H. Prestegard, Nuclear magnetic dipole 
interactions in field-oriented proteins: information for structure determination in solution. 
Proc. Natl. Acad. Sci. 92, 9279–9283 (1995). 
119.  L. Ooi, Principles of X-ray Crystallography (Oxford, 2010) 
120.  J. Drenth, Principles of Protein X-Ray Crystallography (Springer, 2007). 
121.  A. McPherson, J. A. Gavira, Introduction to protein crystallization. Acta Crystallogr. Sect. F 
Structural Biol. Commun. 70, 2–20 (2014). 
122.  D. R. Tobergte, S. Curtis, Crystallography made crystal clear (Elsevier, ed. 3, 2013). 
123.  A. Ilari, C. Savino, Protein structure determination by X-ray crystallography. Methods Mol Biol. 
452, 63–87 (2008). 
124.  A. Sanyal, A. Chen, E. S. Nakayasu, C. S. Lazar, E. Zbornik; C. A. Worby, A. Koller, S. Mattoo, A 
novel link between fic (filamentation induced by cAMP)-mediated adenylylation/AMPylation 







2. The small molecule exotoxin mycolactone and purported
cognate target FKBP12
2.1. Introduction 
Buruli ulcer is a chronic necrotizing skin disease caused by Mycobacterium ulcerans (1, 2). In humans, 
topic infection leads to the systemic diffusion of the mycolactone small molecule toxin, causing local 
analgesia, and impaired inflammation (3). Further, this macrolide has been shown to have pleiotropic 
cellular effects, such as impaired protein translocation, immunosuppressive, and cell-death (4–7). 
Macrolides are natural compounds produced by different organisms, which belong to the polyketide 
class of secondary metabolites mainly produced by cyclization and derivatization of metabolites by 
mega-synthases. Furthermore, these have a wide range of activities, such as antibiotic, antifungal, 
immunosuppressant, and cytotoxic effects in animals (8-11). Due to their high biological activity and 
easy derivatization, these compounds are commonly studied leads in drug discovery (12–14). 
Mycolactone A/B is composed of an invariant 12-membered core macrocyclic lactone ring (in Figure 
2-1 is shown the PG-119 derivative, which is composed of only the lactone ring) and two variable
polyketide-derived highly unsaturated acyl side chains. As such, it exhibits lipid-like characteristics,
such as hydrophobicity. Different bacterial strains express distinct congeners of mycolactone, which





Figure 2-1 – Chemical structures of rapamycin, mycolactone A/B and derivatives, C2 and PG-119. 
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Previously, it has been suggested that mycolactone shares structural and functional features with 
the immunosuppressant rapamycin, an antifungal macrolide produced by Streptomyces 
hygroscopicus (Figure 2-1) (7). In mammals, rapamycin acts as an immunosuppressant through 
inhibition of the mechanistic target of rapamycin complex 1 (mTORC1), a multi-factor sensor protein 
complex involved in the regulation of cell growth, cell proliferation, cell survival, autophagy, 
transcription and translation (16). Rapamycin forms a complex with both mTORC1 and cytosolic 
mTORC1 associated FKBP12 protein (17–19), leading to the direct inhibition of mTORC1 through 
steric hindrance (20). FKBP12 is a known chaperone foldase of proline-rich proteins, which 
catalyzes the cis-trans isomerization of peptidyl-prolyl bonds (21). The exact cellular-target and 
systemic infection molecular mechanisms that underlie the Buruli ulcer disease are currently not 
completely known. Due to the structural and functional similarities between both macrolides, the 
potential interaction between different mycolactone congeners with FKBP12, in comparison with 
the known FKBP12/rapamycin complex, was addressed in this work using solution NMR 
spectroscopy.  
2.2. Material and methods 
Protein expression and purification 
The FKBP12 construct was kindly provided by Alvar Gossert (Novartis, Basel). A single colony was 
picked from a fresh transformation in BL21 (λDE3) competent cells and inoculated into 5 ml 
LB/kanamycin and grown overday at 37°C. At the end of the day, 1 ml was inoculated in 20ml of M9 
minimal medium (15N-ammonium chloride) and grown overnight at 37°C. On the next day, the pre-
inoculum was transferred to 1 l M9 minimal medium and grown at 37°C. At an OD600=0.8 the culture 
was induced with 1 mM IPTG. After 4h of expression the cells were harvested (10min, 5,500 rpm, 4°C, 
SLA3000 rotor), resuspended in 30 ml buffer A (50 mM Tris-HCl, pH=8.0, 300 mM NaCl, 10% (v/v) 
glycerol, 20 mM imidazole) and frozen at -20°C. 
The cells were thawed, DNase I and lysozyme were added, and the solution was stirred for 
approximately 15 min on ice. Afterward, the cells were lysed with a French press (2runs, 1500 PSI), 
and the cell debris was cleared by centrifugation (30 min, 13,000 rpm, 4°C, SS34 rotor). The cleared 
supernatant was applied to a 5 ml pre-equilibrated Ni-NTA gravity column (Genscript, USA) and 
incubated for 30 min at RT on a shaking device. Afterward, the flow-through was collected, the column 
was washed with 10 CV of buffer A, 10 CV 5% of buffer B (buffer A with 150 mM NaCl, 300 mM 
imidazole) and then eluted with 5 CV of 100% buffer B. The elution was left dialyzing in 2 l dialysis 
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buffer (150 mM NaCl, 300 mM imidazole, 1 mM TCEP and 0.5 mM EDTA) with a 3,000 MWCO (Thermo 
Scientific, USA) dialysis membrane at RT.  After 2 h, 50:1 mg of PreScission protease (protein:protease) 
was added and left dialyzing overnight in 5 l dialysis buffer.   
The next day the dialysate was transferred to a 2 x 2.5 l buffer A dialysis for 1h each and then cleared 
by centrifugation (10 min, 12,000 rpm). The cleared dialysate was applied to a 5 ml pre-equilibrated 
Ni-NTA gravity column and incubated for 30 min at RT on a shaking device. Afterward, the cleaved 
protein was collected both in the flow-through and in the buffer A wash (10 CV). PreScision protease 
and un-cleaved protein were eluted with 10 CV 100% buffer B. Both cleaved protein containing 
fractions were pooled, concentrated (Amicon centrifugal filtering device with 5,000 MWCO) and ran 
on a pre-equilibrated S75 SEC column (GE Healthcare; 25 mM KPO4, pH=7), using an Äkta system (GE 
Healthcare, USA). Final yield was 60 mg/l on H2O-based M9 minimal media, determined by UV/Vis 
spectroscopy. An SDS-PAGE confirmed protein purity and the protein pooled stock frozen at -20°C.  
Complex titration sample preparation 
Both rapamycin and mycolactone (A/B, C2, and PG-119 congeners) were kindly provided by Gerd 
Pluschke’s group (Swiss TPH, Basel). Due to the limited solubility of mycolactone in aqueous buffer, all 
samples were prepared with either 1 or 10% (v/v) final DMSO-d6. To ensure a constant percentage of 
DMSO between titration points, each point was prepared separately. A mother solution with FKBP12 
in KPi buffer, NaN3 (0.02% (w/v) final concentration), DSS (1mM final concentration), and D2O (10% 
(v/v) final concentration), was prepared and then mixed with different amounts of mycolactone or 
rapamycin. For each titration point, either mycolactone or rapamycin (1 or 10% (v/v) final DMSO-d6 
concentration) were added. FKBP12 was mixed with each of the macrolides in different ratios up to 
1:10 (FKBP12:macrolide) whenever possible. In addition, complex formation was tested in the 
presence of PPIase activity buffer (50 mM Hepes, pH8, 100 mM NaCl, 5 mM DTT, 0.005% (w/v) NP-40) 
(21). For this, FKBP12 was buffer exchanged twice (using a 5,000 MWCO Amicon centrifugal filtering 
device) with PPIase activity buffer, NaN3 (0.02% (w/v) final concentration), DSS (1 mM final 
concentration), and D2O (10% (v/v) final concentration), before adding Mycolatone A/B (1% (v/v) final 
DMSO-d6 concentration). 
Solution NMR measurement and data analysis 
Standard 2D [15N,1H]-TROSY-HSQC (23) NMR spectra were recorded at 25°C on a Bruker Ascend 700 
spectrometer equipped with a cryogenic triple-resonance probe. NMR data were processed 
with TOPSPIN 3.0 (Bruker Biospin) and analyzed with CCPNMR (24). 
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2‐4,  all  significant  backbone  chemical  shifts  demonstrate  a  good  correlation  between  the  NMR 
titration data and the known X‐ray crystal structure of the protein:ligand complex (26). 
 Figure 2‐4 – Chemical shift perturbation of the FKBP12/rapamycin 1:1 complex in 10% (v/v) DMSO mapped 























and  the complex  in orange.  In B,  the spectra of FKBP12/mycolactone A/B 1:5 complex  in 1% DMSO, apo‐
FKBP12 is shown in grey, and the complex in pink. 
The  FKBP12  PPIase  catalytic  activity  was  previously  studied  with  in  vitro  functional  UV‐Vis 

























In  the  same  conditions,  the  titration  of  FKBP12/mycolactone  A/B,  FKBP12  showed  no  significant 
chemical  shift  perturbations,  indicating  no  complex  formation.  To  further  exclude  DMSO 
concentration as a concern, the titration was repeated with 1% instead of 10% (v/v) DMSO. Still, no 
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significant chemical shift perturbation was observed. To further exclude the tested experimental 
conditions as a factor, the previously described FKBP12 functional activity assay buffer was tested. 
The presence of a small concentration of surfactant, NP-40, was thought to enhance mycolactone’s 
solubility by hindering the formation of micelle-like structures in solution, effectively limiting the 
availability of the compound to interact with FKBP12. Again, mycolactone A/B produced no significant 
chemical shift perturbations. A different mycolactone congener, mycolactone C2, with an extra upper 
acyl chain was also tested with similar results. The macrocyclic PG-119 compound, composed of only 
the lactone ring, was also tested to exclude the possibility both mycolactone A/B and mycolactone C2 
congeners might form micelle-like structures due to the presence of the acyl side chains. Likewise, this 
compound produced no significant chemical shift perturbations. Hence, after testing the 
FKBP12/mycolactone purported interaction under different buffer conditions, DMSO concentrations, 
as well as distinct mycolactone congeners, the lack of significant backbone chemical shift perturbation 
leads to the conclusion that under the described experimental conditions the FKBP12/mycolactone 
complex is not present.  
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3. Cell-free protein expression of eukaryotic proteins 
3.1. Introduction 
Functional and structural protein studies are often limited by the availability of suitable amounts of 
protein. In particular, NMR spectroscopy requires several milligrams of isotopically labeled material. 
Historically, in vivo prokaryotic systems have been extensively used for heterologous protein 
expression. This is mainly due to the system’s robustness and associated low cost of the preparation. 
However, the low achievable yield of important soluble targets, degradation, and aggregation 
represent the main disadvantages of this approach. Alternatively, Eukaryotic systems have compelling 
advantages, such as correct folding and PTM’s. These are however expensive, difficult to set up and 
to maintain, and generally have low yields. In the last decades, in vitro protein synthesis has become 
a viable alternative for the production of problematic proteins. Improvements in both, the system and 
extract preparation, has led to the system’s current state with many advantages such as considerable 
high expressed protein yields, fast expression times, easy screening and robust optimization of 
expression conditions, supplementation with suitable compounds (e.g., membrane mimetics and co-
factors) (1–3), expression of toxic proteins (4, 5) and specifically for NMR the scrambling-free labeled 
amino acid incorporation (6, 7). The system continues to evolve at a fast pace (8, 9). Recently, 
microfluidics cell-free reactors have been introduced (10, 11), which have enabled research towards 
the development of single-dose protein production bioreactors for point-of-care systems (12). 
System description 
In cell-free systems, a target protein is translated by ribosomes extracted from cell lysates. Coupled 
transcription-translation systems combine exogenous DNA transcription with mRNA translation in a 
simultaneous process, avoiding RNA problematic isolation. The required gene of interest is under the 
control of a specific promoter, enabling specific transcription initiation through the addition of an 
exogenous purified RNA polymerase. Which leads to expression specificity and yield enhancement, 
through the increase of copy numbers for the gene of interest. Early systems expressed protein in a 
single container, the so-called batch-mode (13), which were limited to a few hours of expression 
before byproducts would inhibit expression. The continuous exchange method was introduced to 
overcome this issue (14, 15). In this system, the reaction mixture (RM) containing high molecular 
weight compounds is stored in a dialysis membrane surrounded by the feeding mixture (FM) 




















stereospecific  and  region‐specific  isotope  labeling  patterns  optimized  for  NMR,  allowing  spectra 
simplification (19). 
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3.1.1. Cell-free protein expression targets 
The cell-free system is an ideal system for cytotoxic, such as toxins, as well as otherwise complicated 
expression targets, due to its lack of metabolism, and the possibility of supplementation with required 
ligands incompatible with conventional expression systems. The cell-free protein expression system 
robustness was tested with two distinct problematic eukaryotic targets, where expression had proven 
difficult with common expression systems. 
Human Abelson tyrosine kinase 
Protein kinases are key regulators of several cellular processes and have been implicated in 
neurological, cancer, infection, and immunological disorders (20, 21), one of the most pursued classes 
of targets for drug research (22). The high incidence of kinase inhibitor resistance during patient 
treatment has created a high demand for the development of novel drugs (23). Human Abelson 
tyrosine kinase  (Abl) has been implicated in numerous processes (24), such as cell differentiation (25, 
26), cell adhesion (27) and stress response (28). The abnormal, reciprocal translocation between Abl1 
gene in chromosome 9 and the breakpoint cluster region (Bcr) gene in chromosome 22 generates the 
deregulated fusion protein Bcr-Abl associated with chronic myeloid leukemia (29, 30). Imatinib was 
one of the first-generation kinase inhibitors developed, used in the treatment of multiple cancers. 
Despite the early therapeutic success of developed inhibitors, the occurrence of different single point 
mutations in the Bcr-Abl tyrosine kinase domain has led to patient relapse upon treatment due to 
drug resistance. Of these, the “T315I” gatekeeper (GK) mutation exhibits resistance to most currently 
available kinase inhibitor drugs (31, 32). The design of next-generation drugs to overcome drug 
resistance can benefit from structural insights on the gatekeeper mutant and its resistance 
mechanism. 
Human LPS-binding protein 
Septic shock is a sepsis-induced hypotension, which leads to abnormalities in cellular metabolism. 
Patient infection can cause multiple organ failure and death in up to 50% of the cases (33). Bacterial 
infection leads to the immunity system exposure to lipopolysaccharide (LPS), the main component of 
the outer leaflet of Gram-negative bacteria. The septic response has been shown to be associated 
with the LPS-binding protein (LBP) and the opsonic receptor CD14 (34). The interaction complex 
between LPS and LBP is structurally uncharacterized. Due to the high affinity of LBP to LPS, the lack of 
LPS in cell-free expression makes it an ideal system for the expression of LBP. The structural 
characterization of the human LBP and LPS complex should benefit rapid patient diagnosis and 
treatment (35, 36). 
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3.2. Materials and methods 
Cell-free extract preparation 
E. coli S30 cell extract preparation was prepared following published protocols (37). In short, 
harvested A19 cells were washed three times with S30 buffer A1 (10 mM Tris-acetate pH 8.2, 14 mM 
Mg(OAc)2, 0.6 mM KCl, 6 mM β-ME). After resuspension in S30-buffer B1 (10 mM Tris-acetate pH 8.2, 
14 mM Mg(OAc)2, 0.6 mM KCl, 1 mM DTT, 0.1 mM PMSF), cells were lysed using a French press and 
centrifuged twice at 30,000×g, 4°C. To remove endogenous mRNA, the extract was incubated 45 min 
at 42°C and then dialyzed at 4°C overnight against S30-buffer C (10 mM Tris-acetate pH 8.2, 14 mM 
Mg(OAc)2, 0.6 mM KCl, 0.5 mM DTT) with a 12-14 kDa MWCO. To remove the remaining cellular 
debris, the cell extract was centrifuged at 30,000×g, 4°C, aliquoted, flash frozen in liquid nitrogen and 
stored at -80°C. 
DNA amplification 
High amounts of purified target DNA are required for cell-free expression. The isolation of plasmid 
DNA was performed using midiprep or maxiprep kits (Macherey-Nagel) and respective protocols. 
T7 RNA polymerase expression and purification 
A pT7-911 expression plasmid containing T7-RNA polymerase under the control of a T7 promoter 
carrying an ampicillin resistance gene with N-terminal 6xHis-tag was obtained from Stephan Grzesiek 
(Biozentrum, Basel). Using the QuickChange protocol (Agilent), and two consecutive reactions with 
the forward primers 1st half: 5’-CGCATCACCATCACCATCACGGAGAAAACCTGTCCATGAACACG and 2nd 
half: 5’-CCATCACGGAGAAAACCTGTACTTCCAGTCCATGAACACGATTAACA and reverse primers 1st half: 
5’-CGTGTTCATGGACAGGTTTTCTCCGTGATGGTGATGGTGATGCG and 2nd half: 5’-TGTTAATCGTGTTCA 
TGGACTGGAAGTACAGGTTTTCTCCGTGATGG, a TEV cleavage site (residues -ENLYFQ-) was introduced 
between the N-terminal 6xHis-tag and the protein sequence (see Appendix for complete sequence). 
For protein expression single colony was picked from a fresh transformation in BL21 (λDE3) competent 
cells and inoculated into 5 ml Luria Broth (LB) medium with ampicillin (Amp) and grown overday at 
37°C. At the end of the day, 1 ml was inoculated in 20 ml of LB/Amp medium and grown overnight at 
37°C. On the next day, the pre-inoculum was transferred to 1 l LB/Amp medium and grown at 37°C. 
At an OD600=0.8 the culture was induced with 0.5 mM IPTG. After 4h of expression the cells were 
harvested (10 min, 5,500 rpm, 4°C, SLA3000 rotor), resuspended in 30 ml buffer A2 (50 mM Na2HPO4, 
pH=7.5, 300 mM NaCl, 5% glycerol, 1 mM DTT, 20mM imidazole) and frozen at -20°C. 
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For purification the cells were thawed, DNase I (Roche), cOmplete (Roche), and lysozyme (Carl Roth) 
were added and stirred for 15 min on ice. Afterward, the cells were lysed with a French press (twice, 
1500 PSI), and centrifuged (30 min, 16,000×g, 4°C, SS34 rotor). The cleared supernatant was applied 
to a 5 ml pre-equilibrated Ni-NTA gravity column (Genscript) and incubated for 2 h at 4°C on a shaking 
device. Afterward, the flow-through was collected, the column was washed with 10 column volume 
(CV) of buffer A, 5 CV 5% buffer B1 (buffer A1 with 500 mM imidazole) and then eluted with 5CV 75% 
buffer B1. The elution was left dialyzing in 2 l dialysis buffer (10 mM K2HPO4, pH=8, 150 mM NaCl, 1 
mM DTT and 0.5 mM EDTA, 5% (v/v) glycerol) with a 10,000 MWCO (Thermo Scientific) dialysis 
membrane at 4°C.  After 2 h, 30:1 mg of TEV protease (protein:protease) was added and left dialyzing 
overnight in 5 l dialysis buffer at 4°C.   
The next day the dialysate was cleared by centrifugation (10 min, 16,000×g, 4°C). The cleared dialysate 
was applied to a 5 ml pre-equilibrated Ni-NTA gravity column and incubated for 1 h at 4°C on a shaking 
device. Afterward, the cleaved protein was collected both in the flow-through and in the dialysis buffer 
wash (5 CV). TEV protease and un-cleaved protein was eluted with 5 CV 100% buffer B. Both cleaved 
protein-containing fractions were pooled, concentrated (Amicon centrifugal filtering device with 
30,000 MWCO) to about 15–20 mg/ml, and the glycerol adjusted to 50% (v/v), to a final protein 
concentration of 7.5–10 mg/ml. Final yield was 70 mg/l in LB medium, determined by UV/Vis 
spectroscopy. Protein purity was confirmed by an SDS-PAGE, afterward, the protein was aliquoted, 
flash-frozen in liquid nitrogen and stored at -80°C.  
Cell-free protein expression 
A pET-based expression plasmid containing enhanced green fluorescent protein (GFP+) with C-
terminal 6xHis-tag was used as a positive control of expression (38). Both Bcr-Abl, GK-Bcr-Abl and LBP 
constructs were obtained from Stephan Grzesiek’s group (Biozentrum, Basel). For analytical-scale 
expression, 55 μl reactions were prepared in in-house built mini-continuous exchange cell-free (CECF) 
reactors used to optimize expressing conditions, with an optimal FM/RM volume ratio of 14.5. Protein 
expression was left overnight in a thermoshaker at 120 rpm, 30°C in a VWR Incubating Mini Shaker. 
The next day, the reaction mixture was centrifuged (10 min at 10,000 rpm, Eppendorf Centrifuge 5810 
R), and both the resuspended pellet and the supernatant were diluted 1:7 with SDS-buffer and ran on 
an SDS-PAGE. 
For each new batch of T7 RNA polymerase, an analytical-scale reaction comparing the expression of 
GFP+ with the previous T7 RNA polymerase optimal concentration and a range of concentrations for 
the new batch was set up. After overnight expression, the reaction mixture was pipetted from the 






The  recovered  cell‐free  GFP+  supernatants  of  10  analytical‐scale  reactions were  pooled  and  then 
incubated with 0.5 ml of Ni‐NTA beads (Genescript, USA) for 60 min. After incubation, the beads were 
washed  with  5  CV  2.5%  buffer  B1  and  eluted  with  20%  buffer  B1.  The  eluate  was  left  dialyzing 
overnight  in 5  l of 50 mM Hepes pH=7.5, 150 mM NaCl, 2mM DTT, with a 10,000 MWCO (Thermo 
Scientific)  dialysis  membrane  at  RT.  The  following  day,  the  protein  was  concentrated  (Amicon 




The  T7  RNA  polymerase  optimal  concentration  for  protein  expression  was  tested  by  comparing 
performance in the cell‐free system.  For each new batch of T7 RNA polymerase,GK abl an analytical‐
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The cell-free continuous flow system was set up successfully, as shown with the in vitro expression of 
GFP+. The protein was expressed well-folded with a yield between 10-17 mg/ml of cell-free medium, 
a very high-level of expression. The cell-free system was set up primarily for the expression of cytotoxic 
proteins. The in vitro expression system robustness was also tested for the successful soluble 
expression with two significant eukaryotic protein targets of known difficult expression. Human LBP 
expressed in high amounts but insoluble, so no further optimization was tested. Abl and the 
gatekeeper mutant are challenging low expressing proteins in both prokaryotic and eukaryotic 
traditional expressions systems. Cell-free protein expression of the gatekeeper mutant was tested in 
the presence of different commercial kinase inhibitors as well as in the presence of YopH a bacterial 
toxin that targets Abl kinase, to test for protein stabilization. In all cases, almost all protein was 
expressed in the precipitate form. Protein expression optimization was not performed. Co-factors, 
such as chaperones could be used in the future to enhance correct folding and therefore solubility of 
the gatekeeper mutant.  
These two examples also serve to demonstrate the current limitations of in vitro protein expression 
systems. The optimal protein high yield of prokaryotic systems proves to be insufficient possibly due 
to lack of post-translation modifications, required for specific eukaryotic targets. In sub-chapters 4.2 
and 5.2, the successful expression of two labeled protein toxins is shown, using the described in vitro 
cell-free continuous flow protein expression system, in sufficient amounts for NMR studies. 
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4. Structural and conformational elucidation of membrane-bound 
and the membrane-inserted states of pore-forming toxins  
4.1. The bacterial toxin Colicin Ia 
4.1.1. Introduction 
Colicin family 
Colicins are a family of bactericidal proteins produced by E. coli to kill competing susceptible bacterial 
strains. This protein family exhibits distinct cytotoxic activities, and thus far four cytotoxic classes of 
colicin have been identiﬁed: the pore-forming colicins such as ColB, ColIa, and ColN; RNase colicins, 
such as ColE3; DNase colicins such as ColE9; and inhibitors of cell wall synthesis such as ColM (1, 2). 
Though they exhibit different activities, all share domain function and structural organization. All 
members contain three domains each involved in the three parasitic stages: the N-terminal 
translocator domain (T-domain) responsible for outer membrane (OM) translocation; the middle 
receptor binding domain (R-domain) responsible for binding to each respective receptor in the OM of 
susceptible targets (typically OM porins); and the C-domain, which is responsible for the onset of cell 
death (2, 3) (Figure 4-1). Colicins can further be subdivided depending on which host system is 
exploited for their translocation. Group A colicins, exploit E.coli’s Tol-dependent translocation system, 
whereas group B exploits the Ton-dependent translocation system. Both groups hijack and exploit the 
proton motive force of the host cell for colicin insertion into the inner membrane (1, 2).  
Colicins are plasmidic proteins, which are co-expressed with their specific immunity protein. The 
immunity protein inactivates the toxic activity of the colicin, protecting the expressing cell, which is 
achieved through the formation of a tight 1:1 complex with the C-domain. Disassembly of the complex 
occurs upon interaction with the OM receptor of the host cell, prior to OM permeation (2). 
Colicin Ia 
ColIa is a 626 residue (69 kDa) α-helical protein. Structurally, the N-terminal translocator-binding 
domain is separated from the C-terminal pore-forming domain through a long coiled-coil, with the 
receptor-binding domain sitting in between as depicted in Figure 4-1. The C-domain is the cytotoxic 
domain, exhibiting pore-forming activity in the presence of membranes. 
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ColIa  is  part  of  the  colicin  group  B  since  it  exploits  the  host  Ton  system  as  energy  donor  for 
translocation  (4).  Further,  it  uses  the  colicin  I  receptor  (Cir;  70  kDa  β‐barrel  protein)  both  as  the 
receptor (4) and translocator (5) (Figure 4‐2). During OM translocation the R‐domain first binds to Cir 
with high affinity, then the T‐domain acts as a scaffold to subsequently search for a second copy of Cir 
to  which  it  binds  with  lower  affinity.  Subsequently,  the  inner  membrane  (IM)  host  Ton  system 
recognizes  a  TonB  box  in  the  N‐terminal  part  of  ColIa,  which  provides  the  necessary  energy  for 
translocation. This,  in  turn,  leads  to a necessary partial or possibly  full  unfolding of both T and C‐
domain.  It was previously  suggested  that both  the  release of  the  immunity protein and C‐domain 
cleavage occurs at this point. Nevertheless, the order of events and the precise insertion mechanisms 
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energetically  and  sterically  corroborate  the  multimeric  pore  complex  hypothesis.  Interestingly,  it 





















The  early  steps  of  ColIa’s  translocation  are  currently  well  described  in  the  literature,  but  the  C‐
domain’s unfolding and the subsequent insertion mechanisms remain elusive. So far the only structure 











II  site‐directed  mutagenesis  (Agilent)  protocol  and  the  following  primers:  5’‐CATCACAG 
CAGCGGCGAAAACCTGTACTTCCAGCATATGCTCGAGGAG‐3’  and  5’‐CTCCTCGAGCATATGCTGGAAGTAC 














13,000 rpm, 4°C, SS34 rotor). The cleared supernatant was mixed with 5ml of pre-equilibrated Ni-NTA 
beads (Genscript, USA) in a gravity column and incubated for 30min at RT on a shaking device. 
Afterward, the flow-through was collected, the column was washed with 10 column volume (CV) of 
buffer A, 10 CV of 5% buffer B (buffer A with 500 mM imidazole) and then eluted with 5 CV of 75% 
buffer B. The elution was left dialyzing overnight against 5 l Buffer A (pH=7.2) with a 10,000 MWCO 
(Thermo Scientific, USA) dialysis membrane at RT.  
The resulting dialysate was then cleared by centrifugation (10 min, 12,000 rpm) and was run on a 5ml 
Hitrap SP HP (GE Healthcare, USA) prepacked column equilibrated with IEX buffer A (50mM Hepes, 
pH=7.2), using an Äkta (GE Healthcare, USA) system. The protein was eluted with IEX buffer B (IEX 
buffer A supplemented with 1 M NaCl) over a gradient of 10CV. The elution fractions were collected 
pooled, and then incubated with 20:1 mg of tobacco etch virus (TEV) protease (protein:protease ratio), 
and left dialyzing overnight in 5 l TEV dialysis buffer (50 mM Tris-HCl, pH8, 150 mM NaCl, 1 mM DTT 
and 0.5 mM EDTA) with a 10,000 MWCO (Thermo Scientific, USA) dialysis membrane at RT.   
Subsequently, the dialysate was transferred to a 2x 2.5 l buffer A dialysis for 1 h each, and then cleared 
by centrifugation (10 min, 12,000 rpm). The cleared dialysate was applied to a 5ml pre-equilibrated 
Ni-NTA gravity column and incubated for 30 min at RT on a shaking device. Afterward, the cleaved 
protein was collected both in the flow-through and in the buffer A wash (10 CV). TEV protease and un-
cleaved protein were eluted with 10 CV 100% buffer B. Both cleaved protein containing fractions were 
pooled, concentrated with a 5,000 MWCO Amicon centrifugal filtering device (Sartorius, Germany) 
and ran on a pre-equilibrated S75 SEC column (GE Healthcare, USA), (20mM NaOAc, pH=4.5, or 50 
mM Tris-HCl, pH=8) as a polishing step. Protein purity was checked with an SDS-PAGE. 
Bicelle preparation 
A 40% w/w 250 μl stock with q=2.8 DHPC/DMPC (Avanti Polar Lipids, USA) was prepared by weighting 
individual DMPC lipid and DHPC into a sample vial, adding milli-Q water, and left shaking on a vortex 
overnight at 4°C. In the morning the bicelle solution was quickly spun-down and heated at 42°C before 
storing at -20°C. A 10% and 40% stock of CHAPSO/DMPG stock was prepared similarly. 	  
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Crystallization 
An 8% bicelle/ColIa (15-20 mg/ml) solution was prepared from a 40% bicelle stock solution 
(DMPC/DHPC, q=2.8), and incubated for 30 min at 4°C. A series of screening plates were set up using 
the sitting-drop vapor diffusion method with 1:2 bicelle/protein to reservoir solution, against 80 μl 
reservoir, set up manually at 4°C and stored at RT.  
After successful condition screening, crystal quality was improved through crystal seeding. For that, 
the mother liquor was prepared by mixing 4:1 solution of protein buffer (50mM Tris pH8, 300mM 
NaCl) with bicelle stock, and then mixed with 0.1M potassium thiocyanate, 30% w/v PEG monoethyl-
ether 2000 at a 1:2 ratio. Initial crystals were transferred to a sample vial with 50-100µl of mother 
liquor solution, and then crushed with the help of a pipette and subsequently vortexed. The seed stock 
was diluted 1:10 with mother liquor five times, every time using the previous diluted solution to a final 
dilution factor of 1:100,000. For the seeding trials, to 9 µl bicelle/protein mixture 1µl of each seeding 
dilution was added. In each crystallization plates well, 0.5 µl of different bicelle:protein seed dilution 
and 1µl of reservoir solution were pipetted. In the second well, the same solutions were pipetted, 
except for the seed dilution. The screening plate was then sealed and stored at RT. Drops with seeding 
optimized crystals were cryoprotected with a drop of perfluoropolyether, and then the crystals were 
fished and flash frozen in liquid N2.  
Solution NMR measurement and data analysis 
2D [15N,1H]-TROSY-HSQC (13) NMR spectra were recorded at 30°C on a Bruker Ascend 700 
spectrometer equipped with a cryogenic triple-resonance probe. NMR data were processed with 
TOPSPIN 3.2 (Bruker Biospin, USA) and analyzed with CCPNMR (26). For the sequence-specific 
backbone resonance assignment of [U-99%,2H,13C,15N]-ColIa, the following NMR experiments were 
recorded: 2D [15N-1H]-TROSY-HSQC (13), 3D TROSY-HNCA, 3D TROSY-HNCACB, 3D TROSY-HNCO, 3D 
TROSY-HN(CO)CA, and 3D TROSY-HN(CA)CO (14). For side-chain resonance assignment, the following 
NMR experiments were recorded: 3D H(CCO)NH and 3D CC(CO)NH (15, 16). 
4.1.3. Results 
X-ray structure determination of ColIa C-domain 
Bicelles were used as a membrane mimetic in an attempt to study the membrane intermediary and 
inserted states using both NMR spectroscopy and X-ray diffraction, due to the adequate bicelle size 
for solution NMR, and optimal membrane-mimetic properties due to the combination of the soluble 
detergent and lipid environment. At first, crystallization was attempted with the common 
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of  the each ColIa C‐domain structure models  in  stick  representation;  in C,  the backbone  is  colored by  the 
crystal B‐factors where blue is less dynamic and red is more dynamic. 
















































After  the  unsuccessful  crystallization  of  the membrane‐inserted  form  of  ColIa  using  DHPC/DMPC 
bicelles, CHAPSO/DMPG bicelles were tested for membrane interaction. As shown in Figure 4‐13, ColIa 
was titrated with each bicelle type, and the detergents DHPC or CHAPSO as a detergent interaction 
reference  to  rule  out  detergent  solubilization.  In  the  case  of  DHPC,  ColIa  was  shown  to  strongly 
interact with both the detergent and the bicelle, as a dramatical resonance disturbance was observed, 
leading  to  the  conclusion  that  ColIa  strongly  interacts  with  the  detergent,  being  preferentially 










As bicelles have shown to be a successful membrane mimetic for crystallization (19), crystallization 
trials using bicelles as membrane mimetic were set up. The ColIa C-domain crystallization trials 
resulted in the recrystallization of the soluble structure of ColIa, and as such, complete structure 
refinement was not further pursued. 
The promising preliminary crystallization results prompted the procurement of the full backbone and 
sidechain assignment for the soluble form of ColIa, towards the solution study of bicelle interaction, 
through titration studies with different bicelle derivatives in search for the membrane-bound 
intermediate. Residue specific assignment of 90% of backbone residues was achieved for the ColIa C-
domain, where the missing assignments were found to lie on the purported pore-forming hairpin 
helices 8 and 9. Limited H/D-exchange was experimentally ruled out as the cause for peak absence. 
Therefore, it could be concluded that the missing residues are in an intermediate exchange regime, 
which leads to peak broadening and consequent peak vanishing. This result indicates the existence of 
different conformations of the pore-forming hairpin in the soluble form. The secondary structure 
obtained from the NMR chemical shift assignments was found to match closely with the known crystal 
structure. 
Using solution NMR spectroscopy titration studies, the initial success with the DHPC/DMPC bicelles 
was experimentally attributed to detergent solubilization. The alternative CHAPSO detergent was 
shown to only mildly interact with ColIa, and could in principle constitute a starting point for further 
extensive titration studies using different lipid, and pH combinations. Crystallization trials could be 
repeated in parallel with solution NMR, to search for a suitable combination of detergent/lipid 
composition. The lipid screen for a suitable membrane-mimetic could be investigated with other 
methods such as lipidic cubic phase and specifically AFM, which avoid detergents altogether. 	  
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4.2. The proapoptotic Bcl-2 protein Bax 
4.2.1. Introduction 
Bcl-2 homology family and its role in apoptosis 
Apoptosis is a crucial step in the regulation of cellular fate. It is involved in different stages of the life 
cycle of an organism, such as development, tissue homeostasis, and senescence (20–22). Apoptosis is 
also involved in the progress of several diseases, like cancer and several autoimmune diseases (23, 
24). Due to its ubiquity and importance, apoptosis is tightly regulated at different levels. One 
important family of proteins involved in apoptosis is the Bcl-2 (B-cell lymphoma 2) homology family. 
More than 20 members have been described so far, leading to a substantial complex family (20–22, 
25, 26). The different members include four highly structurally conserved Bcl-2 homology (BH) 
domains, outlining both the structural and functional homology between the different members as 
depicted in Figure 4-14. The BH family can be divided into two main groups: antiapoptotic proteins, 
which inhibit apoptosis, such as Bcl-2 and B-cell lymphoma-extra large (Bcl-XL); and proapoptotic 
proteins, which promote it. The proapoptotic BH proteins are further subdivided in death effectors 
(pore-formers) such as the Bcl-2 homologous antagonist/killer (Bak) and the Bcl-2-associated X protein 
(Bax); and the BH3-only activators such as the BH3 interacting domain death agonist (Bid). Different 
group members are regulated by homo- and heterodimerization, which leads to the activation or 
inhibition of its partner (21, 27, 28). A delicate balance between the expression levels and cytoplasm 
availability for each group decides between homeostasis or cell death (21).  
Bcl-2 homology family relation to protein toxins 
The endosymbiotic theory explains the evolution of eukaryotic cells from prokaryote symbiosis. A 
prime example is the mitochondrium, which is derived from prokaryotic cells capable of oxidative 
phosphorylation. This is further emphasized by the fact that mitochondrial DNA is closely related to 
prokaryotic genomes (29). As discussed before, the Bcl-2 homology (BH) family shares a high structural 
homology between both the putative pore-forming domain of the colicin protein family and the 
translocation domain of diphtheria toxin (30, 31). The antiapoptotic members of the BH family form 
inhibiting complexes with the proapoptotic member, which closely resembles the inactivation 
mechanism of colicins C-Domain through complex formation with their co-expressing immunity 
conferring proteins. This has lead to the speculation that the BH family, and therefore apoptosis, has 
its roots in the prokaryote ancestor of mitochondria (32, 33). Although not technically toxins, the 




trigger  cytochrome  c  release  from  mitochondria,  through  pore  formation,  a  crucial  step  within 
apoptosis (34). The transition from the monomeric inactive form to the active cytotoxic membrane‐
inserted form and its precise mechanisms has been named the ‘‘holy grail’’ of apoptosis research (26). 











Many  bacterial  toxins  undergo  a  pH‐dependent  conformational  change  from  the  soluble  to  their 
membrane‐inserted form, whereas the translocation domain of diphtheria toxin and the colicin family 
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of pore-forming toxins are the best-understood examples (35–37). Similar findings were observed for 
several members of the BH family such as Bcl-XL (38), Bcl-2 and Bax (39–41). These observations 
indicate a pH-dependent activation mechanism, leading to the exposure of the membrane-targeting 
domain of Bax and subsequent membrane insertion. Nevertheless, recent experimental work by cell-
free assays (42), EPR (43) and in vitro fluorescence kinetics (44) using liposomes has demonstrated the 
pH-dependent membrane association and pore formation in a broader pH range.  
The exposure of Bax at 43°C to isolated mitochondria leads to the release of cytochrome c, while 
exposure to either antiapoptotic Bcl-XL or cytosolic extract abrogates this effect (45). In addition to its 
pH stability, Bax shows remarkable heat stability (46, 47). These observations suggest an alternative 
activating mechanism for Bax, decoupled from exogenous activators, based on an intermonomeric 
interaction triggered by heat. Heat-shock proteins are known to stabilize sensible proteins to avoid 
cellular stress. Conversely, Bax could have an opposing role, leading under extreme conditions to its 
activation and subsequent cell death. Other indications to the activity of Bax are found in its resistance 
to chaotrops (46). 
The high stability of Bax under extreme conditions suggest the possibility that direct physical or 
chemical agents in vivo can regulate Bax activation. Both temperature and pH-induced conformational 
changes, and its relation to membrane insertion might be either ancient evolutionary rendered 
redundant forms of activation/regulation or actual alternative apoptosis regulation pathways, related 
to cell stress, that further fine tune the precise regulation of apoptosis.  
Conformational changes of Bax 
The structural similar BH family members (Figure 4-14) can be subdivided into groups according to 
their activity. These two groups have opposing roles in apoptosis, either pro or anti. The fact that some 
members have at least two distinct structural forms (the known cytosolic soluble form and the still 
elusive membrane-inserted form) and probably other intermediate conformations leads to a highly 
structurally and functionally complex family.  
Bax was initially discovered through co-immune-precipitation experiments with Bcl-2, a known 
antiapoptotic protein at the time (21). The overexpression of Bax was found to counteract the death 
repressor activity of Bcl-2, leading directly to cell death. Homodimerization and heterodimerization 
between Bcl-2 members were found to regulate available free monomer, in order to facilitate or 
hinder membrane interaction (41).  
The most significant advancement in the field since the description of the soluble structures of 
different BH family members (20–22) was the description of the mechanisms that govern Bax 
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activation and consequent conformation changes mainly by Gavathiotis and coworkers (48, 49). 
Comparing monomeric and ligand-activated Bax or a detergent mimic thereof, using circular 
dichroism, thermofluorescence, and protease digestion (46) as well as NMR spectroscopy to analyze 
ligand based conformational changes (49, 48) a series of events was made clear. First, and in excellent 
agreement with previous data, where Bax N-terminal region had been shown to be displaced from its 
original position to a protease available form (46) exposing an essential hallmark of Bax activation by 
epitope mapping (47, 50, 51); through ligand titration chemical-shift perturbation mapping, the 
initially buried helix 1, 2 loop, was found to be the displaced region (48). This displacement was 
concluded to be the first event in the BH3-only direct activation of Bax. The Bcl-2 member conserved 
BH3 domain (helix 2) implicated in both Bax homodimerization, and interaction with BH3-only 
activator proteins was thought to be responsible for activation propagation (46, 49, 52). This 
hypothesis was tested with the titration of 15N-Bax with a BH3-only peptide mimic, where chemical 
shift mapping showed the binding locus to be at the helix 1, 6 interface, in line with helix 1-2 loop 
displacement (49). The displacement leads to the exposure of Bax BH3 domain, and further activation 
propagation to other monomers, and constitutes the second step in Bax-ligand activation. Finally, in 
the third activation step, the C-terminal helix 9 is displaced from a core-protected helix within the 
monomeric state to a loose helix in the activated form (46, 49, 52). This hydrophobic pocket closely 
resembles the BH3 antiapoptotic pocket of Bcl-2 and Bcl-XL (44, 52). Its hydrophobic nature allows the 
stabilization of several hydrophobic residues of amphiphilic helix 9, increasing Bax solubility through 
the exposure of helix 9 hydrophilic side (52). These three sequential steps outline the fundamental 
interaction between BH3-only activators and Bax, which lead to its activation. Over decades of 
extensive research, a clear set of events has become clear: the ligand-activation of Bax sets in motion 
a chain of events, which results in a conformational reorganization leading to membrane permeation 
and ultimately cell death. 
Pore activity evidence 
One of the most significant issues studying Bax conformational changes is the difficulty in acquiring 
structural information other than the inactive monomer. Different electrophysiological studies 
showed Bax to cause destabilization of the membrane and to form different sized ion-conducting 
channels (39, 40, 44, 53–56). The overall trend in this studies is that two types of channels are 
observed: at first an initial small channel is formed producing simple current recordings, later larger 
channels appear with higher currents and more complex patterns. A general observation is that low 
pH enhanced pore formation (38–40). Both observations suggest that Bax might form different 
oligomeric structures in the membrane. 
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Two recent publications managed to image Bax in the membrane-embedded form by AFM, showing 
Bax pores with diameters ranging from 10–20 to 100–300nm (43, 57). Several studies managed to 
image liposome (43, 58, 59) and nanodisc (60) pores in the presence of Bax, using cryo-EM. In one 
instance, large solitary pores between 50–90nm in size were shown to increase with time and Bax 
concentration (59). Fluorescence microscopy studies show the localized release of fluorescein from 
liposomes upon Bax membrane insertion (44, 61). In both cases, the kinetics of fluorescence loss, 
indicate a concentration-dependent 10–40nm pore. 
The wide range of results from different techniques indicates a heterogeneously shaped pore. 
Depending on conditions such as pH, protein concentration, and the presence of BH3-only members, 
Bax seems to form pores with different sizes and properties. The precise clarification of the 
conformation or conformational steps of Bax in the membrane is vital for the understanding of the 
role of Bax and the Bcl-2 family in apoptosis. 
Bax and the Bcl-2 family have shown to be a remarkable topic of research and discussion within the 
apoptosis field. Which is in part due to its importance in human biology and therefore pharmacological 
industry, but also on its intrinsical complexity. Clarifying the role of each Bcl-2 family member in Bax 
oligomerization, pore formation, and the eventual cascade of effects it leads to, is crucial for the 
elucidation of the complete picture. This is essential in order to understand the underlying 





























4.2.2. Sample preparation and initial characterization of the membrane-inserted 
apoptosis Bax pore by high-resolution solid-state NMR spectroscopy 
Abstract 
The Bcl-2 family of proteins has a central role in the regulation of apoptosis. A mitochondrial 
membrane-bound form of the Bcl-2 protein Bax leads to pore formation and apoptosis. The structural 
and conformational changes Bax experiences towards its membrane-inserted form are currently not 
understood at the atomic level. Here, we show that optimized cell-free expression protocols in 
combination with solution and solid-state NMR experiments allow monitoring these states at atomic 
resolution. Using bicelles as a size-constrained membrane mimetic provides access to a trapped, 
monomeric intermediate step of membrane-associated Bax. Fully formed Bax pores in liposomes, 
corresponding to the apoptosis-active membrane-inserted form of Bax, are studied by solid-state 
NMR spectroscopy. In the membrane-inserted state, the C-terminal helices 7–9 contain dynamic 
residues, and at least one isoleucine residue is shown to be mobile. Our approach provides an 
experimental route to study the pore-state of Bax at atomic-resolution, as well as intermediate states 
of the insertion mechanism. 
Statement of contribution 
In the experimental part, I was responsible for cloning, cell-free system set up, testing and expression 
of Bax protein, solution NMR data acquisition, and NMR data analysis. As for the manuscript, I was 
















one of  the hallmarks of apoptosis  (34).  In  its  soluble  form, Bax  forms a  compact α‐helical bundle, 
sharing remarkable structural similarities with bacterial pore‐forming toxins (Figure 4‐16) (30, 31, 34, 
52).  





Enclosed in its core are the two hydrophobic helices 5 and 6, the putative pore-forming hairpin (67). 
Additionally, the C-terminal transmembrane helix 9 is trapped in the hydrophobic BH3 groove formed 
by helices 2, 3, 4 and 5. Its release and exposure constitute the priming event for oligomerization and 
membrane interaction. Despite the elucidation of the mechanisms that lead to the exposure of helix 
9 (48, 49, 68), structural details of the subsequent events that lead to Bax pore-formation in the 
mitochondrial outer membrane (MOM) are yet unclear. A structural model based on EPR constraints 
has provided substantial information on the helix topology (69), but atomic-resolution information, 
which would be necessary for a full description of the insertion mechanism, is still lacking. Importantly, 
the membrane-inserted, active Bax pore does not possess a single, well-defined oligomeric structure, 
but a variable stoichiometry, making its crystallization particularly challenging. Solid-state NMR 
spectroscopy does not require the formation of repetitive crystal lattices and thus has the potential 
to provide an atomic resolution structure of the membrane-inserted form of Bax. In addition, solution 
NMR spectroscopy can provide structural information of trapped intermediate states. 
The use of NMR spectroscopy requires protein samples that are labeled with stable isotopes. Bax 
expression yields in E.coli cell culture are low, due to membrane self-insertion and consequent 
cytotoxicity, and as a result, multiple liters of cell culture are required for a single isotope-labeled 
protein sample, making extensive studies overly expensive (52). In contrast, cell-free systems often 
circumvent the toxicity problem due to lack of a functional metabolism and cell-delimiting 
membranes. Cell-free expression systems have been successfully used to express challenging protein 
targets such as toxic and transmembrane proteins in milligram amounts for structural biology (70, 71). 
Also, their inherent flexibility and open nature allow manipulation of the reaction conditions and co-
factor supplementation, such as to enhance and stabilize protein targets for high throughput 
production. 
In this work, we describe an optimized cell-free protein expression protocol for the production of an 
isotopically labeled sample of Bax in milligram quantities, suitable and sufficient for solution and solid-
state NMR experiments. Solution NMR spectra of Bax attached to bicelles, and solid-state NMR 
spectra of Bax proteoliposomes were recorded. The data provide concrete insights into the 
conformational changes Bax experiences upon membrane binding and insertion in the presence of 
different membrane mimetics. Our approach opens a new experimental route to study the insertion 
and pore formation mechanism of Bax at the atomic level. 	  
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Materials and Methods 
Cell-free extract preparation 
E.coli S30 cell extract preparation was prepared following published protocols (72). In short, harvested 
A19 cells were washed three times with S30 buffer A (10 mM Tris-acetate pH 8.2, 14 mM Mg(OAc)2, 
0.6 mM KCl, 6 mM β-ME). After resuspension in S30-buffer B (10 mM Tris-acetate pH 8.2, 14 mM 
Mg(OAc)2, 0.6 mM KCl, 1 mM DTT, 0.1mM PMSF), cells were lysed using a French press and centrifuged 
twice at 30’000×g, 4°C. To remove endogenous mRNA, the extract was incubated for 45 min at 42°C 
and then dialyzed at 4°C overnight against S30-buffer C (10 mM Tris-acetate pH 8.2, 14 mM Mg(OAc)2, 
0.6 mM KCl, 0.5 mM DTT) with a 12–14 kDa MWCO. To remove the remaining cellular debris, the cell 
extract was centrifuged at 30’000×g at 4°C, aliquoted, flash frozen in liquid nitrogen and stored at –
80°C. 
Protein expression and purification 
A pET15b-based expression plasmid containing full-length Bax (FL-Bax) with N-terminal His6-tag and 
thrombin cleavage site was obtained from Gerhard Wagner (Harvard Medical School). The N-terminal 
His6-GB1-tag containing construct was obtained by inserting the Bax sequence into pCFX3 (73) using 
the XhoI and the NotI restriction sites. The RF cloning protocol (74) was used to replace the N-terminal 
GB1 tag with the His10-SUMO tag into pCFX3, using the 5’- and 3’-oligonucleotide primers 5’- ATA CCA 
TGT CTG GTT CTC ATC ATC ATC ATC ATC ATC ATC ATC ATC ATG GAG GTT CTG ACT CCG AAG -3’ and 5’- 
GCT GCT CCC CGG ACC CGT CCA TGC CAC CAA TCT GTT CGA GG -3’. 
For analytical scale, 55μl reactions were prepared in home-built mini-continuous exchange cell-free 
(CECF) reactors used to optimize expressing conditions. For preparative-scale protein production, a 
home-built maxi-CECF reactor (72) was used with a 0.5–3.0 ml Slide-A-Lyzer dialysis cassette with a 10 
kDa MWCO (Pierce, Rockford, IL, USA) and a feeding/reaction mixture volume ratio of 14.5. Final 
concentrations of critical components such as PEG8000 (2%), Mg2+ (16 mM) and T7-RNA polymerase 
(9.5 mg/ml of reaction mixture) were carefully optimized for maximal protein expression. Both [U-
15N], and [U-13C,15N] amino acid labeling was achieved with a cell-free twenty amino acid mix 
(Cambridge Isotope Labs) at a final concentration of 0.8 mM in the reaction mixture, and 0.4 mM in 
the feeding chamber. Protein expression was left overnight in a thermoshaker at 120 rpm, 30°C in a 
VWR Incubating Mini Shaker. 
The reaction mixture was centrifuged (10 min at 10’000 rpm, Eppendorf Centrifuge 5810 R) and the 
supernatant was diluted 1:2 with buffer A (25 mM HEPES, 500 mM NaCl, 20 mM imidazole, 1 mM 
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TCEP, pH 7.5) and then incubated with Ni-NTA beads (Thermo Fisher Scientific), pre-equilibrated with 
buffer A, under gentle agitation for 30 min. Afterward, the flow-through was collected, the beads were 
washed with 10% buffer B (25 mM HEPES, 500 mM NaCl, 500 mM imidazole, 1 mM TCEP, pH 7.5) and 
then eluted with buffer B. The elution was buffer exchanged with a PD-10 column (GE Healthcare, 
Piscataway, NJ). The buffer-exchanged eluate was incubated with His6-ULP1 SUMO protease at a 
molar ratio of 50:1 for 30 min, and then with Ni-NTA beads, under gentle agitation for another 30 min. 
Afterward, the flow-through was collected, the beads were washed with 10% buffer B and then buffer 
B. The protein was concentrated and buffer exchanged by ultrafiltration (Vivaspin 10-kDa-cutoff 
concentrator, Vivascience) with NMR buffer (25 mM HEPES, 50 mM NaCl, pH 7.0). The purity of the 
protein was assessed by SDS-PAGE.  
Bicelle preparation and titration 
DMPG/CHAPSO bicelles with a molar lipid/detergent ratio of q=0.3 were prepared at 10 or 40% (w/w) 
stock concentration in water.  The detergent was solubilized in water with slow agitation for 30min. 
The detergent solution was then added to the lipid 
 and incubated for solubilization for 1h. The 40% stock was agitated overnight at 4°C. For the bicelle 
titration, these were added to FL-Bax in defined steps (0.3, 0.5 and 1% (w/v)), resulting in final molar 
ratios of 1:0.52, 1:0.86 and 1:1.72, respectively.  
Liposome preparation 
E. coli polar lipid (ECPL) extract in chloroform solution (Avanti Polar Lipids) was evaporated under a 
stream of nitrogen gas with gentle agitation to form a lipid film and left overnight exposed to vacuum 
in a desiccator to completely dry. The resulting film was re-suspended in buffer (50 mM Tris-HCl, 100 
mM NaCl, pH 7.5) under agitation, to a final concentration of 12.5 mg/ml. The lipids were subjected 
to five freeze-thaw cycles and vortexed in-between. Liposomes were prepared by no less than 10 
passes in a home-built pressure extruder using 100nm polycarbonate filters (Whatman).  
Ni-NTA-Gold negative staining TEM 
Bax protein was incubated with liposomes at a 1:6 w/w ratio of protein:lipid (1:160 molar ratio), for 2 
h at 30°C with agitation. After proteoliposome assembly, 3 µl of the solution was adsorbed to 200-
mesh carbon-coated copper grids rendered hydrophilic by glow-discharging in air for 20s. After 
blotting the excess solution, the grids were stained with a 1:5 dilution of Ni-NTA-Nanogold, rinsed in 
double-distilled water and stained with 2% uranyl acetate. Pictures were taken on a Philips CM10 
equipped with a LaB6 filament and operated at an accelerating voltage of 80 kV. 
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EM and image processing 
For cryo-EM, crystal solution on glow-discharged carbon-coated holey carbon grids (Quantifoil R2/2, 
Quantifoil Micro Tools, Jena, Germany) was blotted and rapidly plunge frozen in liquid-nitrogen-
cooled liquid ethane, using a MarkII Vitrobot (FEI, Eindhoven, Netherlands). The frozen grids were 
transferred to a Gatan-626 cryo-holder and analyzed in a Philips CM200 transmission electron 
microscope, equipped with a field-emission gun and operated at 200 kV. Pictures were taken at a 
nominal magnification of 50,000× using low-dose imaging techniques with an electron dose of 
approximately 5 e−/Å2 and defocus values ranging from 0.5 to 0.9 μm. Images were recorded on 
Kodak SO-163 film, which was developed for 7 min in full-strength Kodak D19 developer solution. 
Image quality was assessed by optical diffraction on a home-built laser diffractometer. The best 
images were digitized using a Heidelberg Primescan D 7100 scanner with a step size of 1 Å/pixel at the 
specimen level. Digital images were processed using the 2dx software suite (75,76), which is based on 
the MRC programs (77). Images were corrected for crystal disorders by three rounds of unbending. 
This was followed by astigmatism and contrast transfer function correction. Symmetry was 
determined using the allspace program (78) within 2dx. 
Proteoliposome preparation and pulldown  
Liposomes were incubated with purified protein at different protein to lipid ratios for 1h at 30°C, and 
ultra-centrifuged at 150’000×g for 1 h in PC tubes (TLA 120.1 rotor, in an OPTIMA Max-XP centrifuge, 
Beckman Coulter, Fullerton, CA). The supernatant was then pipetted out, and the pellet was re-
suspended in liposome buffer. Both supernatant and pellet were analyzed by SDS-PAGE. 
Solution NMR spectroscopy 
2D [15N,1H]-TROSY-HSQC (13) NMR spectra were recorded at 25°C on a Bruker Ascend 700 
spectrometer equipped with a cryogenic triple-resonance probe. 
Solid-state NMR sample preparation 
Proteoliposomes were prepared by mixing ECPL liposomes with 1:3 w/w ratio of protein:lipid (1:80 
molar ratio) and agitated at 30°C overnight. The proteoliposomes were ultracentrifuged overnight at 
150,000×g directly into a 1.9mm rotor (Bruker), using a home-built tool (79) in a Beckman L90-K with 
a swinging-bucket rotor (SW40 Ti, Beckman Coulter, Fullerton, CA). Solid-state NMR spectra were 
recorded on a Bruker Avance III spectrometer at a 20 T static field at 20°C. Several 2D correlation 
experiments were recorded; 2D [1H-13C]-INEPT, 2D [1H-15N]-HSQC, and 2D [13C-13C]-TOBSY (32–37, 
Table 4-1). All spectra were recorded at 35 kHz MAS, except for the 20 ms 2D DARR spectrum which 
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was recorded with 18 kHz MAS frequency. NMR data were processed with Topspin (Bruker) and 
analyzed with CcpNmr (86).  
Table 4-1	–	Experimental parameters for the solid-state NMR spectra. 
Experiment HSQC INEPT INEPT-TOBSY 
MAS frequency [kHz] 35 35 25 
Transfer 1 HN ref-INEPT HC ref-INEPT HC ref-INEPT 
Field [kHz]-1H 100 100 100 
Field [kHz]-13C - 62.5 62.5 
Field [kHz]-15N 50 - - 
Carrier [ppm] - - - 
Time [ms] 10.4 5.0 5.0 
Transfer 2 NH ref-INEPT - TOBSY C9:-
Field [kHz]-1H 100 - -
Field [kHz]-13C 50 - 75 
Carrier [ppm] - - 57 
Time [ms] 10.4 - 8.0 
t1 Increments 2048 512 2048 
Sweep width (t1) [kHz] 12 20 67 
Max acq. time (t1) [ms] 85.0 12.8 15.4 
t2 Increments 4096 3072 3072 
Sweep width (t2) [kHz] 20 85 85 
Max acq. time (t2) [ms] 102.4 18.0 18.0 
1H Decoupling [kHz] 3.0 90 1.1 
Interscan delay [s] 1.33 2.2 2.2 
Number of scans 64 64 32 
Measurement time [h] 48 20 40 
Results 
Optimization of Bax expression by cell-free synthesis 
Cell-free expression systems lack a cellular membrane, making them a method of choice for pore-
forming toxin expression. For solid-state NMR spectroscopy, protein amounts in the mg range are 
required, and we have thus optimized a continuous-exchange cell-free system to produce isotope-
labelled Bax samples. In a first step, to optimize expression and solubility conditions, three different 
Bax constructs were designed: Bax with N-terminal His6-tag in a pET15b vector (pET15b-Bax), Bax with 
N-terminal His6-GB1 solubility tag in a pCFX3 vector (73) (pCFX3-GB1Bax) and Bax with N-terminal 
His10-SUMO tag in a pCFX3 vector (pCFX3-SUMOBax). For each of the constructs, the macromolecular 
crowding concentration was optimized for maximum yield (Fig. 4-17).
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incubation  with  Bax  were  imaged  using  negative‐stain  transmission  electron  microscopy.  Empty 
liposomes appeared flattened upon blotting, but overall their shape seemed intact (Figure 4‐19 A).  
 Figure  4‐19  –  EM  images  of  Bax  proteoliposome  preparations  and  empty  liposome  controls.  A‐  Negative 
staining  EM of  empty  ECPL  liposomes; B‐ Negative  staining  EM of  empty  ECPL  liposomes with Ni‐NTA‐Au 
staining  (negative  control);  C‐  Bax  in  0.025%  DDM  Ni‐NTA‐Au  staining  (positive  control);  D‐  Bax 
proteoliposome  preparation with Ni‐NTA‐Au  staining;  E‐  Cryo‐EM  image  of  empty  liposomes;  F‐  Cryo‐EM 
image of Bax proteoliposomes. Scale bars: 100 nm. 
Bax was  localized using Ni‐NTA‐gold nanoparticles that bind the N‐terminal His6‐tag of FL‐Bax. The 

























among  the  remaining signals,  the N‐terminal  segment of  residues 1–12  remains observable  in  the 
bicelle‐attached form. Thus, this segment remains locally flexible relative to the membrane‐attached 







in  the  active  volume  of  the  rotor.  For  a  given  rotor,  the  amount  of  total  protein  should  thus  be 
maximized. Hence, the protein/lipid ratio of the proteoliposomes needs to be optimized. To obtain 
the maximum protein rotor packing, an ultracentrifugation liposome pull‐down with decreasing mass 
ratios of protein:lipid  (from 1:1  to 1:3) was  tested. At a 1:3 mass  ratio,  close  to all of  the protein 
associated with the liposomes (Figure 4‐21).  
 Figure 4‐21 – Bax liposome ultracentrifuge pulldown experiment to test the maximum protein to lipid mass 
ratio;  Liposome bound Bax  (P),  and  soluble Bax  (S)  are  shown  for different  ratios  and both  free Bax  and 
liposome controls. Optimal w/w ratio is shown to be 1:3, where maximum protein appears in the P form. 
Soluble Bax control shows no protein in the insoluble fraction. Note that Bax liposome insertion is Bax 
specific,  as  none  of  the  impurities  present  in  the  soluble  fraction  are  found  on  the  pellet. 
Proteoliposomes with a 1:3 ratio were thus used for the solid‐state experiments. 








based  experiment,  showing  the  highly  flexible  residues  of  liposome‐inserted  Bax.  Around  20–30 
resonances are observed, among these several peaks correspond to the N‐terminal resonances shown 
before to remain mobile upon membrane  interaction. Overall  the spectrum shows a highly similar 
resonance  fingerprint  in  comparison  with  the  bicelle‐bound  2D‐TROSY‐HSQC  (Figure  4‐20  B).  The 
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Table  4‐2  –  Number  of  spin  systems  types  identified  from  the  2D  [13C,13C]‐INEPT‐TOBSY  spectrum  (with 
individually identified cross‐peaks in parenthesis) and 2D [1H,13C]‐INEPT (with individually identified carbon 
resonances in parenthesis). 
Residues  2D [13C,13C]‐INEPT‐TOBSY  2D [1H,13C]‐INEPT  Free Bax 
flexible  
Bax total  
Alanine    4 (4 C1 C  2  14 
Arginine  1 (CC CC  2 (2 C; 2 C)  2  11 
Aspartate  1 (CC)    6  13 
Glutamine   2 (CC  2 (2 C)  2  9 
Glutamate  1 (CC  2 (2 C)  3  10 
Glycine  n.a.  6 (6 C  13  21 
Isoleucine  1 (C1C1; C2C; C2C)  1 (1 C 1 C1 C  0  9 
Leucine  1 (C2C1; C2CC1CCC)  2 (2 C1 C1 C  4  22 
Lysine  1 (CCCCCC  4 (3 C; 4 C; 1 C)  3  9 
Methionine    2 (2 C; 2 C  4  8 
Proline  1 (CC)    6  8 
Serine  1 (CC)  3 (2 C 3 C)  5  11 
Threonine    5 (5 C 5 C 1 C2)  4  13 
Valine  1 (CC  3 (1 C C  3  11 
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Discussion  
In the present work, we have employed cell-free protein expression to improve the total production 
yield of isotope-labeled samples of the protein Bax. This approach circumvents the toxicity and low 
expression yields in standard E.coli expression systems (52, 88). Furthermore, the tendency of Bax to 
aggregate and oligomerize was partially resolved through the fusion with different solubility tags. Bax 
cell-free expression was optimized to ~0.33mg/ml, forming the basis for cost-efficient production of 
labeled samples (90). The use of solubilizing detergents during Bax purification is described at length 
among the literature (50, 51, 90, 91). Different detergents have also been shown to activate Bax (50, 
92), distinctly than the BH3-only activators (92). After an initial detergent trial, in order to avoid 
interpretation mistakes, the use of detergents to stabilize Bax was precluded.  
Bax 2D [15N,1H]-TROSY-HSQC resonance dispersion demonstrates the expression of a well-folded 
protein (Figure 4-20 A), which superimposes quite well with the known sequence-specific resonance 
assignment (52). The membrane-bound form of Bax (Figure 4-20 B) shows that the N-terminal flexible 
region is not in contact with the bicelle, tumbling at a different regime. It seems the slower tumbling 
regime due to bicelle immobilization leads to peak broadening concealing non-flexible resonances, 
this transition from rigid to flexible evidence a C-terminal structural rearrangement upon membrane 
binding. Additional resonances with lower intensity are also seen. These point to flexible residues in a 
distinct conformation from the free form. The small diameter of q=0.3 bicelles (~8 nm) (87) could 
comfortably accommodate a 20 kDa (3-4 nm diameter) globular particle (93), possibly a dimer, but 
would effectively halt oligomerization. It seems reasonable to conclude that a pore intermediate is 
bound to the membrane, with several flexible residues including the N-terminal. The bicelle acts as a 
cage by physically trapping this membrane-bound intermediate limiting further oligomerization. This 
observation is supported by the accepted mechanism of Bax activation, where a single 
monomer/dimer is found in the mitochondria outer membrane in equilibrium with the free form. This 
intermediate is purportedly rescued from pore-formation by Bcl-Xl and other antiapoptotic members 
or led further down the oligomerization path by t-Bid and other BH3-only activators (28, 94). 
High-temperature incubation has been shown before to activate Bax in a similar way to BH3-only 
members, allowing membrane insertion (43). EM imaging of proteoliposomes confirms Bax to both 
co-localize and rupture the liposomal membrane after high-temperature incubation (SFig.2). The 
liposome pull-down shows that after protein/lipid mass ratio optimization, essentially all Bax is 
inserted into the liposomes. The presence of limited sets of resonances in both flexible and mobile 
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residues in the solid-state NMR spectra (Fig. 4) and the absence of apparent peak doubling suggests a 
high degree of conformational homogeneity by the individual Bax molecules in our preparation. 
Comparing the liposome-inserted Bax 2D [1H,15N]-HSQC with the bicelle bound  (Figure 4-20 B and C), 
the N-terminal region is found to be mobile in both cases. The flexible residues evidenced in both the 
2D [13C,13C]-INEPT-TOBSY and 2D [1H,13C]-INEPT show that at least 33 residues out of the 192 amino 
acids remain flexible (Table 4-2). Interestingly, one isoleucine is found to be flexible in the membrane-
inserted state, as opposed to none within the free form. It seems liposome-inserted Bax is a step 
further in the oligomerization path, where most residues are buried in the membrane, and the flexible 
residues experience an entirely different chemical environment, which explains the different chemical 
shifts for flexible regions, between the liposome inserted and the free form. The presence of a flexible 
isoleucine unequivocally evidences an overall structure rearrangement upon membrane interaction. 
Overall, by combining cell-free expression with solid-state NMR spectroscopy, this work has enabled 
the first high-resolution spectra of membrane-inserted Bax. Whereas additional work will be required 
to provide structural information via sequence-specific resonance assignments, our approach opens 
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5. Structural and functional characterization of FIC-domain post-
translational modification protein toxins  
5.1. FIC-domain protein family 
FIC-domain proteins are conserved in all domains of life, including viruses (1, 2), from bacteria to 
higher eukaryotes (3). They were first identified in an E.coli filamentation growth-arrest phenotype 
caused by cyclic-AMP, where the first identified FIC protein, the gain-of-function FIC-1, was found to 
be the responsible agent (4). Recently, FIC proteins were identified as PTM proteins (5, 6), and since 
several different target proteins have been identified, such as GTPases, unstructured protein 
segments, and bacterial enzymes (7–9), which implicates FIC proteins in distinct roles of cell function, 
such as pathogenicity (6, 8, 10), regulation of translation and stress response (11), as well as eukaryotic 
signal transduction (12).  
FIC-domain proteins, which contain the FIC motif HPFx(D/E)GN(G/K)RxxR catalyze the transfer of a 
phosphoryl-containing group, through cleavage of a substrate phosphodiester bond, onto a target 
protein (13). The transfer of an AMP moiety, from an ATP substrate, is termed adenylylation, or 
AMPylation, and the respective catalytic enzymes, adenylyl (or AMP) transferases. FIC proteins with a 
degenerate FIC motif were found to display distinct catalytic activities, such as phosphocholine 
transferase (8) and kinase (11). In these, the catalytic site binds a nucleotide substrate in an inverse 
conformation compared to the canonical FIC motif, leading to the transfer of a different moiety. This 
is exemplified by the Death on curing (Doc) protein toxin, which catalyzes the transfer of a phosphate 
group from ATP onto the target protein (11), and the Ankyrin repeat-containing protein X (AnkX), 
which catalyzes the transfer of a phosphocholine from CDP-choline (8). Apart from the FIC-domain 
proteins PTM modification of target proteins, FIC proteins have also been shown to be able to catalyze 
automodification reactions such as auto-AMPylation (13–15). 
The conserved FIC-domain is structurally defined by an α-helical core enclosing the catalytic motif 
(Figure 5-1). Further, a flexible loop found in most FIC proteins so far, termed flap, located in close 
proximity to the active site, aid target docking through the formation of an intermolecular antiparallel 
β-sheet-like element (15, 16). The invariant catalytic histidine deprotonates an incoming target side-
chain hydroxyl group, which subsequently enables the nucleophilic attack on the ligand 



















Class  I FIC proteins,  found exclusively  in bacteria, are classic  toxin/antitoxin complexes, where  the 
antitoxin bears the αinh motif. Expression of the FIC‐domain protein alone is therefore highly toxic to 





Class II of FIC-domain proteins 
Approximately 80% of all identified FIC-domain proteins so far belong to Class II of FIC proteins.  They 
are characterized by an N-terminal regulatory domain αinh, relative to the FIC-domain (2). The 
underlying mechanism and function of this large class of FIC proteins, which includes the human FIC 
homologue HypE, is mostly unknown at this point. Apart from HypE, briefly discussed in the first 
chapter, another Class II member the Shewanella oneidensis FIC (SoFIC) (Figure 5-1 B) AMP transferase 
was the first described Class II FIC protein (21). Additionally to the N-terminal αinh, SoFIC exhibits a C-
terminal winged helix-turn-helix dimerization domain postulated to be a DNA-binding domain (21).  
Class III of FIC-domain proteins 
This class of FIC proteins is a small group of bacterial single-domain proteins, characterized by a C-
terminal regulatory domain αinh relative to the FIC-domain (2). Interestingly, E.coli expression of an 
inhibition-relieved mutant of class III Fic-domain protein NmFIC (Figure 5-1 C) was shown to result in 
the AMPylation of GyrB only, one of the two identified Fic targets (2). The precise role of the 
AMPylation and consequent toxic inhibition of GyrB within the cellular context is not yet completely 
understood. NmFIC protein conformation and function were further explored in the framework of this 
thesis, described below in sections 5.2 and 5.3. 
Other FIC-domain proteins 
FIC-domain proteins, with different catalytic transferase activities, have different regulatory groups. 
The Doc/Prevents host death (Phd) protein toxin/antitoxin complex and its homologues, belong to a 
particular class of FIC proteins, characterized by an incomplete FIC catalytic core, with a distinct 
catalytic motif (3, 22, 23). The Phd antitoxin replaces the αinh as the substrate-binding regulator, with 
a non-canonical block of the catalytic site (11). Some FIC-domain proteins even lack a regulatory group 
altogether like the Vibrio parahaemolyticus type III effector (VopS) and the Histophilus somni 






























5.2. The Neisseria meningitidis FIC protein 
5.2.1. Intrinsic regulation of FIC-domain AMP-transferases by oligomerization and 
auto-modification 
In this publication, the complex autoinhibition mechanism of NmFIC is described. NmFIC from 
Neisseria meningitidis undergoes a complex oligomerization dependent control, where 
autoadenylation in cis leads to its activation and subsequent adenylylation of its target, the DNA 
gyrase subunit B GyrB. The autoadenylated form of NmFIC slows down the growth of ectopically 
expressing E.coli due to its toxicity, leading to very low protein expression. Cell-free expression was 
key to circumvent this problem and obtain sufficient amounts for the NMR structural characterization 
and analysis of the dynamic properties of the autoadenylated form of NmFIC. This data was crucial in 
the comparison of non- and autoadenylated FIC in the identification of the conformational changes 
induced upon automodification, and relation to its function. 
Statement of contributions 
I was responsible for the cell-free protein expression of autoadenylated NmFIC, NMR data collection, 
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5.3. FIC-domain protein interaction with cognate target GyrB 
5.3.1. Introduction 
Most FIC-domain proteins catalyze the transfer of a phosphoryl-containing group onto a target 
protein, through cleavage of a substrate phosphodiester bond (13). Of these, those with a canonical 
FIC motif catalyze the transfer of an AMP group, from a bound ATP molecule. Their catalytic activity is 
under the control of a regulatory element termed αinh, and can be largely classified based on the αinh 
position in relation to the catalytic motif. The αinh regulatory element contains a conserved motif, 
where an invariant glutamate carboxyl side-chain binds an invariant arginine part of the FIC motif, 
effectively preventing competent binding of the nucleotide substrate (2). The physiological αinh toxin 
inhibition relief mechanism is not yet clear (19).  
The first identified FIC protein: the gain-of-function FIC-1 was found to be the responsible agent In the 
E.coli filamentation growth-arrest phenotype caused by cyclic-AMP (4). Since then, different bacterial 
FIC-domain proteins have been identified as host-targeted secreted pathogenic factors (6,25); 
however, the biological function of most FIC-domain proteins remains elusive. VbhTA is a 
toxin/antitoxin protein complex expressed by the mammalian pathogen Bartonella schoenbuchensis 
(26). The antitoxin VbhA is encoded upstream of the VbhT gene. The full-length VbhT protein contains 
a C-terminal Bep intracellular delivery (BID) domain, a type IV secretion system signal, responsible for 
the secretion of the toxin-antitoxin complex onto bacterial or mammalian host-cell targets. Upon host-
delivery the inactivating complex is thought to disassemble, leading to the mature active form of the 
toxin (19). In the inactive form, VbhA forms a tight complex with VbhT, where the conserved residues 
S20 and specifically, E24 bind R147 of VbhT, obstructing the competent binding of ATP within the 
catalytic site on the FIC-domain motif. In vitro, the VbhAE24G inhibition relief mutant was shown to 
mimic the antitoxin release mechanism behaving similarly as the active form of VbhT (2). Recently, 
the VbhT was linked to an E.coli growth-arrest phenotype, correlating with the AMPylation of two 
target proteins: the homologous subunits B of the bacterial type II topoisomerases DNA gyrase GyrB, 
and topoisomerase IV (topo IV) ParE (20). Topoisomerases control DNA topology through DNA 
catenation and de-catenation, ensuring DNA and RNA polymerase function, playing an essential role 
in healthy cell growth and function (24). VbhT catalyzes the post-translational modification of the 
catalytical site of both ATPases, effectively blocking its intrinsic ATPase activity, causing the abrogation 
of their biological function and ensuing cell growth arrest (2, 20). The structural characterization of 
the VbhTA/GyrB apo, as well as the nucleotide-bound complexes is described below. 
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5.3.2. Material and methods  
Protein purification 
NmFICE102R,E156R,H107A monomer mutant, the VbhA/VbhT(1-198) protein complex, the inhibition relieved 
VbhAE24G/VbhT mutant and the GyrB(1-220) ATPase-domain proteins, termed from here on NmFICmono 
VbhTA, VbhTAE24G, and GyrB, were expressed and purified as previously described in (2, 13, 27). In 
short, NmFICmono and VbhTAE24G were expressed in the E. coli BL21-AI strain, while VbhTA and GyrB 
were expressed in the E. coli BL21 (lDE3) strain, either in LB or M9 medium (15N-ammonium chloride) 
for isotopically labeled protein ([U-15N]). Subsequently, each protein was purified by Ni-NTA affinity 
chromatography followed by size exclusion chromatography. An additional anion exchange 
chromatography step was performed for GyrB.  
Solution NMR measurement and data analysis 
Standard 2D [15N,1H]-TROSY-HSQC (28) NMR spectra were recorded at 25°C on a Bruker Ascend 700 
spectrometer equipped with a cryogenic triple-resonance probe running Topspin 3.0 (Bruker, USA). 
NMR data were processed with PROSA (29) and analyzed with CARA (30). Chemical shift perturbations 
were calculated with: 
𝐶𝑆𝑃 = %&'Δδ( 𝐻	- )/0 + '0.2 ∗ Δδ( 𝑁	-7 )/08,	
where Δδ(1H) and Δδ(15N) are the chemical shift changes of the 1H and 15N nuclei, respectively. The 
earlier determined sequence-specific resonance assignments of NmFICmono, as well as the published 
assignment of GyrB, was were used for the sequence-specific analysis (31). 
VbhTA/GyrB apo and nucleotide complexes co-crystallization 
For crystallization, the protein complex was assembled by incubating GyrB 1:1 with the VbhTA 
complex, and subsequently purified on an S200 increase 10/300 GL gel filtration column (GE 
Healthcare) equilibrated with buffer G (20 mM phosphate buffer pH 7.2, 40 mM KCL, 40 mM NaCl, 
1mM EDTA, 2 mM DTT) using an Äkta (GE Healthcare, USA) system. The complex fractions were 
analyzed by SDS-PAGE and concentrated to ~10 mg/ml by ultrafiltration with a 10,000 MWCO Amicon 
centrifugal filtering device (Sartorius, Germany). 
Crystals of the protein complex were obtained using the sitting-drop vapor diffusion method after 
mixing 0.2 μl protein solution with 0.2 μl of reservoir solution, equilibrating against 80 μl of reservoir 
solution. Crystallization trials were set up using protein-complex screens (ProPlex, and NR-LBD, 



























pH  7.2,  40  mM  KCl,  40  mM  NaCl,  1mM  EDTA,  2mM  DTT)  was  found  to  stabilize  both  GyrB  and 
NmFICmono (31). Subsequently, the NMR‐titration was repeated with buffer G, as shown in Figure 5‐3. 




increased  chemical  shift  perturbation.  In particular,  the measured  chemical  shift perturbations vs. 
sequence plot show three localized perturbation areas, the N‐terminus residues 14‐16, residues 65‐
72, and residues 145‐159, as well as intensity drops within these regions (Figure 5‐3). The optimized 





















flap  region  (depicted  in  red,  previously  in  Figure  5‐1  A)  and  the  catalytic  domain.  The  displaced 
backbone chemical shifts reveal a clear interaction interface, specifically in the surface representation 
(Figure  5‐5 A).  Conversely,  on  the GyrB  side,  the  structure mapped  chemical  shift  perturbation  is 
spread through the N‐terminal side of the protein, showing a larger binding interface, including the 
loop containing  the AMPylation  target Y109  (Figure 5‐5 B).  In  the  surface  representation, no clear 




the  mutation  of  the  catalytic  H107  to  an  alanine  could  as  well,  hinder  ligand  binding,  and 
consequentially complex formation. 
Solution NMR titration VbhT/VbhA complex with cognate target GyrB 
As  shown  for  the  NmFICmono  and  GyrB  proteins,  the  same  approach  was  followed  to  study  the 












as  well  as  several  intensity  decreased  peaks,  and  a  few  peaks  broadened  beyond  detection.  The 
chemical shift perturbation plot shows several areas with significant chemical shift perturbation, in 
particular, the N‐terminal region. The intensity drop plot, evidence an overall significant decrease of 







slow  exchange  indicate  the  existence  of  a  stable  and  distinct  form  of  this  region  within  the 







dimerization  interface,  specifically  on  the  N‐terminal  side  of  the  GyrB  protein,  as  well  as  several 
stretches around the ATP‐lid loop containing the AMPylation target residue Y109. 
AMP transferase and GyrB catalytic complex formation 




the  assembled  NmFICmono/GyrB  protein  complex, matches  the  chromatogram  sum  of  each  of  the 
individual proteins. This was once again confirmed by SDS‐PAGE, where each protein  is present  in 






The VbhTA/GyrB complexes were  similarly applied  to a gel  filtration column equilibrated with  the 





peak.  This  behavior was  further  confirmed  through  the  gel  filtration  of  the  reloaded VbhTA/GyrB 









































fishing and  freezing,  the cryo‐protection was  first optimized. Both perfluoropolyether and glycerol 
were tested, as well as a stepwise increase of glycerol through drop transfer, but ultimately a 20% 
glycerol/reservoir mixture showed the best results as assayed visually from crystal appearance (cracks 






   	 VbhTA/GyrB 
Wavelength 1 
Resolution range 42.19 – 2.01 (2.09 – 2.01) 
Space group P 21 21 21 
Unit cell 76.81 84.07 84.38; 90 90 90 
Total reflections 73611 (7156) 
Unique reflections 36836 (3589) 
Multiplicity 2.0 (2.0) 
Completeness (%) 1.00 (0.99) 
Mean I/sigma(I) 20.45 (1.95) 
Wilson B-factor 24.82 
R-merge 0.04241 (0.4745) 
R-meas 0.05997 (0.469) 
CC1/2 0.997 (0.799) 
CC* 0.999 (0.969) 
Reflections used in refinement 36826 (3586) 
Reflections used for R-free 1906 (203) 
R-work 0.1755 (0.3123) 
R-free 0.2158 (0.3555) 
CC(work) 0.962 (0.771) 
CC(free) 0.942 (0.695) 
Number of non-hydrogen atoms 4187 
  macromolecules 3667 
Protein residues 458 
RMS(bonds) 0.004 
RMS(angles) 0.57 
Ramachandran favored (%) 99 
Ramachandran allowed (%) 0.67 
Ramachandran outliers (%) 0 
Rotamer outliers (%) 1.5 
Clashscore 3.97 
Average B-factor 32.57 
  macromolecules 31.39 
  solvent 40.69 
Number of TLS groups 14 
Statistics for the highest-resolution shell are shown in parentheses. 
 
VbhTA/GyrB apo complex structure 
Of the tested crystals, ~50% showed a unit cell similar to the known VbhTA structure (PDB ID: 3SHG), 
whereas 50% revealed a space group and unit cell dimensions distinct from each of the known 
individual crystal structures. From the several collected datasets, for the novel crystal form, the 
highest resolution dataset was picked for data processing. Due to initial less than optimal crystal cryo-
protection, the crystals of the apo-complex diffraction patterns displayed several ice rings, some of 
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structural  differences  were  observed  on  the  VbhTA  side.  However,  on  the  GyrB  side,  two major 






indicated  the  GyrB  N‐terminal  tilting;  and  in  II,  the  ATP‐lid  loop  catalytic  approximation  conformational 
rearrangements induced upon complex binding. 















lid  loop’s  targeted  segment  containing  target  residue  Y109  (blue).  In  A,  is  shown  the  flap‐lock  in  stick 

















 Figure 5‐18 – Overlay of  the VbhTA/GyrB  co‐crystallized  complex with GyrB dimer  (PDB  ID: 1ei1).  In A,  is 










logical  step. As such, co‐crystallization with different nucleotides was attempted,  in search  for  the 
nucleotide‐bound  forms.  At  first,  for  the nucleotide‐bound  complex,  the protein  complex was  co‐
crystallized in the presence of either 5mM AMP or ATP, using a newly designed fine screen based on 
the above‐described apo‐complex crystal buffer conditions, varying both buffer pH (7.4‐8), and PEG 
8k  concentration  (15‐22%  (w/v)).  Crystals  were  observed  to  grow  preferentially  at  higher 
concentrations of PEG, and with a  few exceptions, at  lower pH. VbhTA/GyrB co‐crystallized  in  the 
presence of AMP nucleotides, but not with ATP, as crystals grew in none of the tested conditions. Of 
the several AMP co‐crystallized crystals, those with higher dimensions and finer edges were selected 
and  cryo‐protected  with  the  improved  cryo‐protection  protocol,  using  the  respective  reservoir 


































































The  crystallization  of  the  non‐competent  nucleotide‐bound  complex  led  to  the  pursuit  of  the 
crystallization  of  VbhTAE24G  inhibition  relieved  mutant  with  GyrB,  in  the  presence  of  ATP.  The 
crystallization was attempted  through both ATP co‐crystallization and nucleotide  soaking with  the 






















































conformational  similarity  with  an  RMSD  of  0.639  for  the  VbhTA/complex  backbone  alignment  (5 
alignment cycles, 1546 to 1546 atoms out of 1772 total atoms). The provisional structural model of 












The  achievement  of NmFICmono backbone  resonance  specific  assignment,  discussed  in  chapter  5.2, 
paved  the  way  towards  the  target  complex  titration  studies  using  solution  NMR  spectroscopy. 
Chemical  shift  perturbation  and  intensity  drop  for  the  NmFICmono/GyrB  NMR  titration  experiment 
evidenced  the binding  residues  for both proteins, which when mapped onto  the  known  structure 
helped  identify  the  possible  binding  interface  on  each  interaction  partner,  specifically  on  the 
NmFICmono  side,  where  a  clear  binding  interface  was  observed.  On  the  NmFICmono  side,  binding 
interface expressly demonstrated the suspected role of the flap region on GyrB binding. Conversely, 
on the GyrB side, the binding interface was less clear. Both NmFIC E102R‐E156R mutations introduced 
previously  for  the  soluble  study  of  the monomeric  form  of  the  protein,  are  situated  in  the  here 
evidenced NmFIC/GyrB binding  interface. The charge  inversion of  the E2R mutated  residues could 
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induce  charge  repulsion  between  interacting  residues  of  each  protein,  disturbing  not  only  the 








drop  mapping  uncovered  a  compact  complex  binding  interface  on  the  N‐terminal  side  of  GyrB. 
Additionally, NMR titration studies allowed the optimization of GyrB‐stabilizing buffer, resulting in the 
formation of  a  stable  complex,  confirmed by  size‐exclusion  chromatography,  and SDS‐PAGE. After 
initial  crystallization  trials  and  condition  optimization,  the  co‐eluting  complex  was  successfully 
crystallized.  The  VbhTA/GyrB  complex  structure,  demonstrated  the  conformational  changes  each 
partner  experiences  upon  complex  formation.  The  VbhT  N‐terminal  loop  adopts  a  conformation 
where it opens up the catalytic site upon GyrB binding. On the GyrB side, as evidenced by the NMR‐
titrations,  GyrB’s  N‐terminus  adopts  a  conformation  away  from  the  binding  interface.  GyrB’s  N‐
terminal loop is responsible for holding the active GyrB dimer in place upon ATP substrate binding, 
essential  for GyrB catalytic dimer  formation, ATPase activity,  and enzyme  turnover  (40).  The GyrB 
protein is then effectively held through β‐augmentation between the VbhT flap loop’s target dock and 
GyrBs ATP‐lid targeted segment as an antiparallel β‐sheet‐like structure; as well as an intermolecular 
salt‐bridge  between  two  residues  side‐chains,  tightly  binding  GyrB  in  place  for  AMPylation.  This 
structural  feature  matches  well  with  the  observed  distinct  structural  state  observed  with  NMR‐
spectroscopy,  showing  slow  chemical  exchange  on  the  NMR‐time  scale,  as  well  as  the  known 







AMPylated  complexes.  At  first,  the  nucleotide‐bound  complex was  crystallized  in  the  presence  of 
AMP.  The  resulting  structure  showed  an AMP moiety  bound  to  the  catalytic  site,  albeit  in  a  non‐
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competent manner,  as  the alpha‐phosphate oxygen  sits  in  the Y109 hydroxyl nucleotide unbound 
position,  resulting  in charge repulsion. VbhA antitoxin contains  the canonical FIC αinh motif, where 
residue  E24  binds  VbhT’s  R147  catalytic  residue  responsible  for  competent  ATP  binding.  The 
physiological  inhibition relief mechanism of  the wild‐type protein remains currently unknown.  It  is 
believed  that  translocation  of  the  FIC‐domain  into  the  host  cell,  leads  to  the  unfolding  of  the  TA 
complex,  where  VbhT  translocates  unaccompanied,  in  a  similar  manner  to  the  proposed  colicin 
translocation unfolding mechanism (discussed in chapter 4.2) (19). In vitro, this effect is mimicked by 
an inhibition‐relieved mutant, through the replacement of the glutamate residue to a glycine (2, 13). 





 Figure  5‐23  –  Comparison  between  the  catalytic  sites  of  both  apo  and  nucleotide‐bound  co‐crystallized 
complexes. In A is shown the apo complex catalytic site, in B, the AMP‐bound complex, in C the ADP‐bound 
co‐crystallized complex, and  in D the superposition between AMP moiety (from the AMP‐bound complex) 




With the solution of apo-complex and AMP-bound structures (Figure 5-23 A-B), it became clear the 
role of the αinh VbhA E24 residue on the competent binding of ATP, later demonstrated in the ADP 
bound structure (Figure 5-23 C). In Figure 5-23 D is depicted the possible structure of the AMPylated 
product complex, through the overlay of the apo complex’s Y109 residue, and the AMP-bound 
complex AMP moiety, in good agreement with the known FIC-target IbpA/Cdc42 complex (42).  
5.4. Conclusion 
Solution NMR spectroscopy and X-ray crystallization were explored in an integrated fashion for the 
conformational and structural characterization of both NmFIC auto-AMPylation and VbhTA/GyrB 
complex. This approach allowed the biological contextualization of high-resolution crystal structures 
with NMR dynamical data, to unravel further details of each proteins physiological function. In both 
cases solution NMR spectroscopy allowed the study of the dynamic properties of each protein and 
protein complexes, helping uncover aspects such as NmFIC conformational changes induced upon 
automodification, GyrBs minimal construct and optimal conditions for complex formation; each of 
these crucial for the conformational characterization of each protein. Whereas X-ray crystallography, 
allowed the fast resolution of several high-quality atomic resolution structures, aiding the uncovering 
of each proteins structure, conformational changes, and their catalytic function.  	  
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6.1. Protein sequences 



















FKBP12 (11.974 kDa; ε280: 9970 M-1cm-1): 
MGSSHHHHHHLEVLFQ/GPGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEV
IRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE 
Neisseria meningitidis FIC (22.143 kDA; ε280: 24410 M-1cm-1): 
MHHHHHHMKSIDEQSLHNARRLFESGDIDRIEVGTTAGLQQIHRYLFGGLYDFAGQIREDNISKGGFRFANAMYL
KEALVKIEQMPERTFEEIIAKYVRMNIAHPFLEGNGRSTRIWLDLVLKKNLKKVVNWQNVSKTLYLQAMERSPVND
LRLRFLLKDNLTDDVDNREIIFKGIEQSYYYEGYEKG 	  
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Bartonella schoenbuchensis VbhA (7.270 kDa; ε280: 1490 M-1cm-1): 
MLSEEEIEYRRRDARNALASQRLEGLEPDPQVVAQMERVVVGELETSDVIKDLMERIKREEI 	  
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H – 6x or 10x His tag 
ENLYFQ – TEV protease cleavage sequence 
LEVLFQ – PreSc protease cleavage sequence 
LVPRGS – Thrombin protease cleavage sequence 
IEGR – FactorXa protease cleavage sequence 
AA – SUMO tag 










Abl, Abelson tyrosine kinase 
AFM, atomic-force microscopy 
ASC, apoptosis-associated speck-like protein containing a CARD 
AMP, adenosine triphosphate 
ARF, ADP-ribosylation factor 
Bcr, breakpoint cluster region 
bGB1, basic mutant of B1 domain of protein G from Streptococcus sp 
BiP, Binding immunoglobulin protein 
b-OG, beta-octylglucoside 
β-ME, β-mercaptoethanol 
BMCF, batch mode cell-free 
Brij35, polyoxyethylene-(23)-lauryl-ether 
bp, bair pairs 
CARD, Caspase activation and recruitment domains 
C-domain, channel domain 
CECF, continuous-exchange cell-free 
Cir, colicin I receptor 
Col, colicin 
COSY, correlation spectroscopy 
cryo-EM, cryo-electron microscopy 
DDM, n-dodecyl-D-maltoside  
DHPC, 1,2-hexanoyl-sn-glycero-3-phosphocoline 
diC7PC, 1,2-diheptanoyl-sn-glycero-3-phosphocoline 
DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine  
DMPG, 1,2-dimyristoyl-sn-glycero-3-phospho-(1'-rac-glycerol)  
DMSO, dimethylsulphoxide 
DNA, deoxyribonucleic acid 
Doc, Death on curing 
DTT, 1,4-dithiothreitol 
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EDTA, ethylenediaminetetraacetic acid 
ER, endoplasmatic reticulum 
FIC, filamentation induced by cyclic AMP 
FK-506, Tacrolimus 
FKBP12, human peptidyl-prolyl cis-trans isomerase FK506 binding protein 1A, 12kDa 
FM, feeding mixture 
GB1, B1 domain of protein G from Streptococcus sp. 
GFP, green fluorescent protein from Aequorea victoria 
GK, gatekeeper 
GSH, reduced glutathione 
GSSG, oxidized glutathione 
GTP, guanosine triphosphate 
GyrB, Escherichia coli DNA topoisomerase IIa Gyrase B 
HSQC, heteronuclear single quantum coherence 
hAblK1GK, human Abelson kinase 1 T351I gatekeeper mutant 
hLBP, human Lipopolysaccharide Binding Protein 
HypE, Huntingtin yeast-interaction protein E 
IbpA, Histophilus somni Immunoglobulin binding protein A 
IM, inner membrane 
IPTG, isopropyl-β-D-thiogalactopyranoside 
kDa, kiloDalton 
LB, Luria Bertani 
LBP, lipopolysaccharide-binding protein 
LPS, lipopolysaccharide 
MAS, Magic-angle spinning 
mRNA, messenger ribonucleic acid 
mTORC1, mammalian target of rapamycin complex 1 
MWCO, molecular weight cut-off  
NmFIC, Neisseria meningitidis FIC protein 
NmFICmono, Neisseria meningitidis FIC protein monomeric mutant 
NMR, nuclear magnetic resonance 
NOE, nuclear Overhauser effect 
NOESY, nuclear Overhauser effect spectroscopy  
OAc, acetate 
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OM, outer membrane 
PCR, polymerase chain reaction 
PFT, pore-forming toxin 
Phd, Prevents host death 
PMSF, phenylmethylsulfonylfluoride 
ppm, parts per million 
PreSc, PreScission 
PTM, post-translational modification 
R-domain, receptor domain 
rf, radiofrequency 
RM, reaction mixture 
rmsd, root-mean-square deviation 
RNA, ribonucleic acid 
SAIL, stereo-array isotope labeling 
SDS-PAGE, sodium dodecyl-sulfate polyacrylamide gel electrophoresis 
SoFIC, Shewanella oneidensis FIC 
T-domain, translocation domain 
T7 RNAp, RNA polymerase from bacteriophage T7 
TCEP, tris(2-carboxyethyl)phosphine 
TEV, tobacco etch virus 
TOCSY, total correlation spectroscopy 
TritonX100, polyethylene-glycol P-1,1,3,3-tetramethyl- butylphenyl-ether  
tRNA, transfer ribonucleic acid 
TROSY, transverse relaxation optimized spectroscopy 
VbhTA, Bartonella schoenbuchensis octopine Ti plasmid virulence B homologous T and A complex 
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